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This thesis examines the various interventions proposed for the management of poor 
responders undergoing IVF treatment. I began by performing a systematic review and meta-
analysis to identify the ideal controlled ovarian hyperstimulation (COH) regimen for women 
with poor ovarian response undergoing IVF. The systematic review found the evidence to be 
inconsistent and inconclusive. The poor responders intervention trial (PRINT) was thus 
conceived. PRINT is an RCT comparing the gonadotrophin releasing hormone (GnRH) 
agonist long versus the GnRH agonist short versus the GnRH antagonist regimens for poor 
responders undergoing IVF. Results of PRINT showed the GnRH agonist long regimen to be 
efficacious. 
 
The relationship between egg numbers and live birth following IVF is poorly understood. I 
set out to investigate this by examining a large cohort of IVF cycles. I was able to 
demonstrate a strong association between egg numbers and live birth following IVF and 
justify the use of egg numbers as a primary outcome for PRINT. 
 
A frequent scenario faced in the management of women who have a poor response is whether 
to continue with their current IVF cycle or to cancel and start again on the assumption that 
there could be intercycle variability. I examined this hypothesis by comparing two 
consecutive IVF cycles with identical COH regimens. There was no significant intercycle 
variability in poor responders suggesting that the more cost effective option would be to 




Over the last decade a number of studies have been published on the use of androgen 
supplementation in poor responders. I conducted a systematic review and meta-analysis 
which demonstrated potential benefit from androgen supplementation but highlighted the 
shortcomings in the existing evidence. Finally, I conclude my thesis by examining the 
evidence behind some common clinical practices in the management of poor responders with 


















1.1 History and milestones in in vitro fertilisation 
The essence of mammalian reproduction is the fusion of a sperm and oocyte to form a 
conceptus which eventually results in a new individual. In nature, these important events of 
fertilisation occur within the bodies of the female. The quintessence of assisted reproduction 
is that a third party, the reproductive endocrinologist-embryologist directly manipulates 
sperm and/ or oocyte to enhance the probability of achieving a pregnancy. 
 
The success of human clinical in vitro fertilisation (IVF) rests on solid foundations of many 
years of animal research. The evolution of assisted reproduction as it is practised today came 
through the following historical milestones: In 1878, Schenk made the first attempts to 
fertilise mammalian eggs extracorporally by adding a drop of epididymal sperm to rabbit 
eggs suspended in follicular fluid together with uterine mucus (Schenk, 1878). In 1890, 
Heape reported the successful transfer of embryos from a donor rabbit to a recipient, resulting 
in the first surrogate birth (Heape, 1890). In 1930, Gregory Pincus, carried out experiments 
on in vitro fertilisation in rabbits by obtaining tubal rabbit eggs and incubating with sperm 
(Pincus, 1930). These experiments were unsuccessful as none of the oocytes exposed to 
sperm and transferred into the fallopian tubes resulted in offspring. Pincus subsequently 
teamed up with Enzman and continued his work on in vitro fertilisation. They published their 
results in 1934 when they obtained offspring after incubating rabbit eggs and spermatozoa in 
vitro and transferring them into the fallopian tubes of a recipient (Pincus and Enzman, 1934). 
However, it was later debated that the fertilisation process might have actually taken place in 
the fallopian tubes of the recipient rabbit and not in vitro and many remained sceptical, partly 





The first successful in vitro penetration of spermatozoa through the zona pellucida of rabbit 
oocytes, and penetration of a fertilising spermatozoon into the oocyte cytoplasm was reported 
by Moricard in 1950 (Moricard, 1950). Following in vitro incubation of rabbit oocytes with 
sperm under relatively anaerobic conditions, penetration into the zona pellucida was 
demonstrated in 14 of the 21 oocytes by 47 spermatozoa and into the oocyte cytoplasm in 
five oocytes by a single spermatozoon. There was however no demonstration of pronuclei 
formation, syngamy or cleavage. 
 
The separate discovery by Austin (1951) and by Chang (1951) that ejaculated or epididymal 
rabbit sperm had to undergo some kind of physiological change within the female tract 
(which they termed ‘capacitation’) before they were capable of passing through the zona 
pellucida  was of critical importance for the subsequent success of fertilisation in vitro 
(Austin, 1951; Chang, 1951). Soon after this, Thibault and his colleagues reported successful 
fertilisation of rabbit eggs in vitro using in vivo capacitated sperm which had been recovered 
from the uterus (Dauzier et al., 1954; Thibault et al., 1954; Dauzier and Thibault, 1956). 
However, since their evidence of fertilisation was based on histological examination of the 
zygotes, the validity and reliability of all the supposedly successful in vitro fertilisation 
experiments were questioned because of the ambiguity of cytological criteria as evidence of 
fertilisation (Austin, 1951; Smith, 1951; Chang, 1957). It was felt that fertilisation in vitro 
may not be sufficiently proven unless living offspring were obtained. Finally in 1959, Chang 
reported the first live births from in vitro fertilised rabbit oocytes, obtained by incubation of 
newly ovulated oocytes with in vivo capacitated uterine sperm (Chang, 1959). In 1968, 
Whittingham obtained normal offspring by fertilising mouse oocytes in vitro with uterine 
spermatozoa, culturing the fertilised oocytes to the two-cell stage and then transferring them 




The first attempts to fertilise human eggs in vitro were made by John Rock and Miriam 
Menkin. They obtained oocytes from ovarian tissue that was removed from women 
undergoing laparotomy for a variety of conditions and carried out numerous experiments to 
achieve in vitro fertilisation. This work was carried out long before the concept of ethical 
approval for research in humans was introduced. Following a number of modifications in 
their experimental methods over time, they reported the first successful in vitro fertilisation 
and cleavage of human eggs (Rock and Menkin, 1944; Menkin and Rock, 1948). The eggs 
obtained from the ovarian tissue were washed in media and incubated in the woman’s serum 
for 27 hours; they were then exposed to sperm suspension for one hour and transferred into 
fresh serum from post menopausal women. Although four among the several eggs 
manipulated in their experiments cleaved into two or three cells, whether these eggs were 
really fertilized remained uncertain in view of the possibility of parthenogenetic activation 
and cleavage during culture. 
 
A very significant step towards subsequent successful human in vitro fertilisation was the in 
vitro capacitation of sperm, first reported in hamster spermatozoa (Yanagimachi and Chang, 
1963). Since the fertilisation rate was lower with epididymal compared to in vivo capacitated 
sperm, the ability to induce capacitation in vitro opened up the possibility of human in vitro 
fertilisation with ejaculated sperm from the male partner. 
 
In addition to capacitated sperm, mature oocytes capable of fertilising are required for 
successful in vitro fertilisation. Although post-dictyate ovarian and mature oocytes could be 
obtained in large numbers in animals after stimulation with luteinizing hormone (LH) either 




regimens were then thought to be unsuitable for humans as the effect of exogenous hormones 
was inadequately understood. This impediment to obtaining mature oocytes was overcome by 
the successful in vitro maturation of mice, pig, cow, sheep, monkey and human oocytes after 
careful consideration of the culture conditions (Edwards, 1965). 
 
Edwards and his colleagues reported the first in vitro fertilisation of in vitro matured human 
oocytes with ejaculated and in vitro capacitated spermatozoa obtained by adapting the 
conditions that had led to successful capacitation of hamster spermatozoa and fertilisation in 
vitro (Edwards et al., 1969). Fifty six human eggs were inseminated with spermatozoa, of 
which 34 matured in vitro and seven eggs had well formed pronuclei. Though this marked a 
turning point for reproductive biology, there remained the main challenge of retrieval of 
oocytes in women. 
 
Soon after, Robert Edwards was able to continue his work on in vitro fertilisation and 
cleavage of human oocytes by collaborating with gynaecologist Patrick Steptoe who could 
obtain oocytes retrieved laparoscopically from women (Edwards et al., 1970). The women 
were given injections of human menopausal gonadotrophin (hMG) and chorionic 
gonadotrophin (hCG) to induce follicular growth and maturation and laparoscopy was 
performed 30-32 hours after the hCG injection when each follicle was aspirated in an attempt 
to recover mature oocytes. The retrieved oocytes were suspended in droplets consisting of 
follicular fluid and one of four culture media being tested for ability to support fertilisation. 
Following incubation for one to four hours at 37º C, the oocytes were washed through two 
changes of the media and then placed in suspensions of spermatozoa. Between 12-15 hours 




various other media for cleavage. Edwards and Steptoe demonstrated that human embryos 
could be cultured in vitro to the 16-cell stage (Steptoe and Edwards, 1970). This was soon 
followed by successful in vitro culture of human embryos to the fully expanded blastocyst 
stage (Steptoe et al., 1971). 
 
In 1973, two very early biochemical pregnancies following IVF treatment were reported by a 
team from Melbourne, Australia (De Kretzer et al., 1973) which were the first reported 
pregnancies from IVF treatment in women. In 1976, Edwards and Steptoe reported a tubal 
pregnancy following the transfer into the uterus of a human embryo cultured in vitro (Steptoe 
and Edwards, 1976) but there was huge scepticism as to whether this had resulted from IVF 
and embryo transfer or had happened unexpectedly but spontaneously.  Finally, Louise 
Brown, the world’s first IVF baby was born on 25th July 1978 (Steptoe and Edwards, 1978), a 
pregnancy that was achieved after laparoscopic retrieval of an oocyte in a natural cycle, in 
vitro fertilisation and transfer of an 8-cell embryo into the uterus. This was soon followed by 
successes in other countries. The first IVF live birth in Australia was in 1980 (Candice Reed, 
third reported birth following IVF), in 1981 in the USA (Elizabeth Carr) and in 1982 in 
Sweden and France (Cohen et al., 2005). 
 
Other historical milestones include, the first donor egg pregnancy and live birth reported in 
December 1983 in a woman with premature ovarian failure (Lutjen et al., 1984), the first 
frozen embryo pregnancy in 1983 (Trounson et al., 1983) and the first frozen embryo birth in 
1984 of Zoe Leyland (Downing et al., 1985). The first live births following intra cytoplasmic 
sperm injection (ICSI) were reported in 1992 (Palermo et al., 1992). ICSI was reported as a 




impaired sperm characteristics, and has since revolutionised the treatment of male factor 
infertility. 
 
1.2 History of superovulation in IVF treatment 
Initial IVF attempts to encourage more and better ooctye development involved hormonal 
stimulation of the ovaries using either human pituitary gonadotrophins (hPG) (Talbot et al., 
1976) or clomiphene citrate with human chorionic gonadotrophin (hCG) (Lopata et al., 
1978). However, repeated failure led to concern over the effects of the gonadotrophin and the 
high oestrogen level on the endometrium prompting a change to the use of the natural cycle. 
Since the first IVF birth in 1978 occurred on a natural cycle, most researchers concentrated 
on the use of natural cycles for the next few years. However, the timing of oocyte retrieval in 
natural cycles depended on the detection of the spontaneous surge of LH, and necessitated 
women being subjected to serial urinary LH assays every four hours. There was difficulty in 
not being able to predict precisely the time of ovulation, and also there was a low oocyte 
retrieval rate per aspirated follicle – usually only one follicle and one egg (or none) for each 
procedure. 
 
The difficulties with natural cycle IVF rekindled interest in superovulated IVF cycles. In 
1980 a small controlled trial was carried out in 50 patients with tubal infertility by a 
Melbourne team led by Alan Trounson which compared natural cycle versus clomiphene 
citrate versus clomiphene citrate and hCG (Trounson et al., 1981). This demonstrated that 
pregnancies could also be established with clomiphene citrate and hCG or clomiphene citrate 
and natural LH release. This was the first demonstration that IVF pregnancy could be 




laparoscopy for oocyte retrieval, and consequently a more efficient use of available resources. 
In 1981, a team in Norfolk, USA lead by Georgeanna and Howard Jones used hMG to induce 
multiple follicular development. The stimulation was very gentle compared with modern 
practices and, on their 13th endeavour they were successful with Judy Carr which resulted in 
the birth of the first IVF baby in the USA in December of that year (Jones, 2003). 
 
A vital clinical milestone to optimising the success of IVF treatment was thus introduction of 
controlled ovarian hyperstimulation (COH) regimens. An understanding of the physiology of 
ovulation is important to comprehend the pharmacology of drugs and stimulation regimens 
used in IVF treatment which is discussed below. 
 
1.3 Folliculogenesis 
During a normal menstrual cycle following the involution of the corpus luteum and the 
consequent fall in oestrogen production, follicle stimulating hormone (FSH) levels rise during 
the luteo-follicular transition (le Nestour et al., 1993). This rise in FSH stimulates the 
recruitment of a cohort of follicles. Further development of these follicles during the 
follicular phase is dependent on continued stimulation by gonadotrophins. According to the 
concept of an FSH ‘threshold’ postulated by Brown in 1978, FSH concentrations need to 
exceed a certain level for follicular development to proceed (Brown, 1978). When the FSH 
‘threshold’ is surpassed in a normal cycle, it stimulates the growth of a cohort of small antral 
follicles and ensures further preovulatory follicular development (Fauser and van Heusden, 
1997; Macklon and Fauser, 1998). The duration of this period in which the ‘threshold’ is 
exceeded (FSH ‘window’) is limited in the normal cycle as there follows a decrease in FSH 




period leads to multiple follicular development. In a normal menstrual cycle, the single 
follicle continues to develop despite falling levels of FSH due to an increased sensitivity to 
the hormone (Hsueh, 1986), but the remaining follicles undergo atresia in response to the 
declining levels of FSH. Ovulation is triggered by a sharp and transient surge in LH as a 
result of the positive feedback from oestrogen produced by the dominant growing pre 
ovulatory follicle. 
 
Thus the duration of elevated FSH plays an important role in determining the number of 
follicles that will undergo further development. In superovulation regimens, a supra-
physiological dose of FSH is used to recruit multiple ovarian follicles with higher ‘threshold’ 
FSH requirements. Exogenous administration of FSH stimulates the granulosa cells of the 





Figure 1.1: Human follicle development – FSH threshold/ window concept 
Schematic representation of the intercycle rise in serum FSH levels (FSH threshold/ window 
concept), and follicle growth dynamics (recruitment, selection and dominance) during the 




1.4 Drugs used for COH in IVF treatment 
Since the early days of IVF, the results of IVF treatment have much improved with a 32.3% 
live birth rate being reported for women aged under 35 years in the UK in the year 2009 
(http://www.hfea.gov.uk/ivf-success-rate.html). The paradigm shift from natural unifollicular 
IVF treatment cycles to multifollicular stimulated IVF treatment cycles has been an important 
contributing factor to this improvement, largely enabled by the availability of ovulation 
inducing drugs such as clomiphene citrate, human menopausal gonadotrophin (hMG; 
menotropins), and subsequent generations of products. It lead to the evolution of the concept 
of COH whereby the ovaries are stimulated to produce high numbers of good quality oocytes 




facilitate a yield of good numbers of high quality embryos available for transfer, thereby 
increasing the probability of pregnancy. 
 
Another aspect of COH is better cycle control and the avoidance of a premature LH surge 
which, by either premature ovulation or inappropriate luteinisation before oocyte pick-up, 
leads to high cycle cancellation and poor pregnancy rates. In conjunction with the drugs that 
cause multifollicular stimulation of the ovaries, pituitary suppression with gonadotrophin 
releasing hormone (GnRH) analogues which eliminate endogenous gonadotrophin 
interference with exogenous superovulation regimens, and timed administration of hCG 
which has a similar structure but a prolonged half-life compared to LH, serve as adjuvants for 
the control of all events in the process of COH. 
 
The following gives an overview of the drugs used for COH in IVF treatment. 
 
1.4.1  Clomiphene citrate 
Clomiphene citrate is a synthetic oestrogen agonist/ antagonist which has been used for 
ovulation induction in anovulatory women for many years (then known as MRL-41) since its 
first results were published in 1961 (Greenblatt et al., 1961). Clomiphene or Clomid® (2-
[para-(2-chloro-l,2-diphenylvinyl)phenoxy] triethylamine citrate) is a racemic mixture of cis 
and trans isomers. The cis (inert) and trans (active) isomers are called zuclomiphene and 
enclomiphene respectively. The racemic mixture, which is administered to induce ovulation, 





Clomiphene and oestrogen have similar chemical structures, but important differences exist. 
Clomiphene occupies the receptors for a longer time compared with oestrogen (weeks versus 
hours), and affects the hypothalamic activity by binding to the oestrogenic receptors thereby 
decreasing the number of receptors available. The hypothalamus and pituitary falsely 
interpret this as indicating low oestrogen levels. This triggers a negative feedback mechanism 
that results in secretion of GnRH by the hypothalamus which in turn results in the increased 
production of pituitary gonadotrophins (FSH and LH) that effect ovarian stimulation. The 
overall increases in FSH levels during clomiphene treatment are reported to be around 50 – 
60% (Polson et al., 1989; Butzow et al., 1995). 
 
Clomiphene is usually administered orally as tablets for five days starting between days two 
to six of a cycle after spontaneous menstruation or progesterone induced withdrawal 
bleeding, or from days 5 to 9 as stated in the product information. Available as a 50 
milligram tablet it is usually administered in doses of 50, 100 or 150 mg/ day. 
 














1.4.2  Gonadotrophins 
Human gonadotrophins include FSH, LH and hCG. They are complex heterodimeric 
glycoproteins which consist of two non-covalently linked, non-identical peptide chains 
designated as α- and β-subunits. The α-subunit is common to all three gonadotrophins as well 
as to thyroid stimulating hormone. It consists of 92 amino acid residues in the same sequence 
with five disulphide bonds and two carbohydrate moieties. The β-subunits are unique to each 
gonadotrophin and confer biological activity and specificity. They are comprised of amino 
acid chains of variable length (116 – 147 amino acids) and contain six disulphide bonds 
Zuclomiphene 
















(Pierce and Parsons, 1981). Gonadotrophins are water soluble and highly degradable by 
enzymes present in the gastrointestinal tract. They must therefore be administered 
parenterally (intramuscularly or subcutaneously). 
 
During the 1950s, efforts were made to obtain human gonadotrophins for therapeutic use by 
extracting them from cadaver pituitary glands and urine of postmenopausal women. 
Successful induction of ovulation and pregnancy with human pituitary gonadotrophins (hPG) 
was first reported by Gemzell and his co-workers in 1958 and in 1960 respectively (Gemzell 
et al., 1958, 1960). Human urinary menopausal gonadotrophins were first semipurified by 
Piero Donini by passing bulk urine from post -menopausal donors over a kaolin extract 
followed by removal of high and low molecular weight impurities by chromatography. The 
product referred to as menotropin was first effectively used in a hypogonadotrophic 
hypogonadal woman to induce ovulation and pregnancy (Lunenfeld et al., 1962).  
 
The successful therapeutic use of urinary gonadotrophins started with the first generation 
product human menopausal gonadotropin (hMG) or menotropin, which contained 75 IU of 
FSH and 75 IU of LH in each standard ampoule. This was followed in the early 1980s by the 
development of urofollitropin, the second generation product from which the LH activity had 
been reduced to 0.1 IU/ 75 IU FSH (Seibel et al., 1985). Subsequently, the third generation 
product, highly purified urofollitropin (Metrodin HP®) with practically no residual LH 
activity was developed in the early 1990s. Due to its enhanced purity with very small amount 
of protein, Metrodin HP® could be administered subcutaneously which is an advantage over 
the previous generations which had to be administered intramuscularly. The more recent 




acid (DNA) technology, by genetically engineered Chinese hamster ovary cells. This is 
recombinant human FSH (r-FSH or follitropin) which is free of LH and contains less than 1% 
of contaminant proteins (Shoham and Insler, 1996). There are two preparations of r-FSH that 
are commercially available for clinical use, follitropin-α (Gonal F®, Merck-Serono, 
Switzerland) and follitropin-β (Puregon®, Organon, Netherlands). 
 
The LH surge that induces germinal vesicle breakdown and ovulation in a natural menstrual 
cycle is not reliable in stimulated multifollicular cycles necessitating artificial triggering of 
ovulation. hCG which is naturally produced by the human placenta and excreted in large 
quantities in the urine of pregnant women bears a close molecular resemblance to LH and has 
a similar effect on the LH receptor. hCG can be used because of its longer serum half life (36 
hours) compared to the short serum half life of LH (108 – 148 minutes) (Wide et al., 2010), 
thus avoiding the inconvenience of repeated administration. Administration of hCG results in 
luteinisation of the granulosa cells, progesterone biosynthesis, resumption of meiosis, oocyte 
maturation and subsequent follicular rupture 36 – 40 hours later. It is administered after the 
stimulated development of mature preovulatory follicles in order to induce maturation, but 
egg retrieval is undertaken before ovulation. The preparations of hCG that are available for 
clinical use are chorionic gonadotrophin (Pregnyl®, Organon, Netherlands) and 
choriogonadotropin-α (Ovitrelle®, Merck-Serono, Switzerland). 
 
1.4.3  Gonadotrophin releasing hormone agonists 
GnRH is a decapeptide (Glu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2) synthesised in the 
cell bodies of the hypothalamic neurons and secreted by their terminals into the hypophyseal-




cells in the pituitary to release FSH and LH (Schally et al., 1971a), which in turn stimulate 
gonadal production of sex steroids and gametogenesis. 
 




Certain unique characteristics mark the physiology of GnRH. Firstly, its endogenous 
secretion is pulsatile in nature with a frequency of around 60 minutes, which is required for 
the gonadotrophs to secrete the gonadotrophins (Belchetz et al., 1978). Secondly, continous 
stimulation of the pituitary either by natural sequence GnRH or by long acting GnRH 
agonists desensitises gonadotrophin secretion, resulting in gonadal suppression (Belchetz et 
al., 1978).  Knobil was the first to demonstrate that in order to induce ovulation, GnRH must 
be administered not continuously but in pulses precisely spaced in time (Knobil, 1980).  
 
The isolation, elucidation of the structure and synthesis of the hypothalamic GnRH was 
accomplished simultaneously by two teams led by Andrew Schally and Roger Guillemin in 
1971 (Matsuo, 1971; Schally et al., 1971b; Amoss et al., 1971) for which they shared the 
Nobel Prize in Physiology or Medicine in 1977 for ‘the discoveries of the peptide hormones 
of the brain’. The GnRH agonists were developed by structural modification at two main 
positions (6 and 10) of the native GnRH molecule. These agonistic analogues have a higher 
biological potency and a prolonged half life compared to endogenous GnRH. Replacement of 




the glycine residue at position number six of the native GnRH by a large hydrophobic and 
lipophilic D-amino acid leads to increased resistance to enzymatic degradation and 
prolongation of the half life by reducing renal excretion through increased plasma protein 
binding and fat storage. Substitution of the glycine residue at position number ten (the C-
terminus) with NH-ethylamide adds to the stability of the molecule and its resistance to 
enzymatic degradation. 
 
GnRH agonist administration initially induces an increase in the number of GnRH receptors 
(up regulation) and the liberation of high amounts of LH and FSH from the pituitary. Within 
12 hours of administration, the so called ‘flare-effect’ leads to a five-fold elevation of FSH, 
ten-fold increase in LH and a four-fold rise in oestradiol (Lemay et al., 1984). Continuous 
administration of GnRH agonists causes internalisation of the GnRH receptor complex and a 
decrease in the number of receptors, referred to as ‘down regulation’. This causes a 
paradoxical suppression of pituitary gonadotrophin synthesis and release (desensitisation). 
The decreased FSH and LH levels result in the arrest of follicular development and a fall in 
sex steroid levels. This is the basis for the clinical use of GnRH agonists. This pituitary 
blockade lasts during treatment with the GnRH agonist but is completely reversed after 
discontinuation of therapy with normalisation of the menstrual cycle within six weeks 
(Reissmann et al., 1995). 
 
Porter and colleagues were one of the first group to report the use of GnRH agonists to 
prevent premature LH surge in IVF treatment cycles thereby improving the outcome (Porter 
et al., 1984). The possibility of desensitising the pituitary gland with GnRH agonists and thus 




to their use prior to and during stimulation with gonadotrophins in some IVF treatment 
regimens. 
 
GnRH agonists being small peptides are easily degradable by gastrointestinal enzymes and 
cannot be administered orally. They are administered parenterally, either via the intranasal 
route, buserelin (Suprecur®, Sanofi-Aventis, UK) and nafarelin (Synarel®, Pharmacia, UK), 
depot preparations, triptorelin (Decapeptyl SR®, Ispen, UK, Gonapeptyl Depot®, Ferring, 
UK), intramuscular and subcutaneous injections, leuprorelin (Prostap®, Wyeth, UK) or 
subcutaneous injections goserelin (Zoladex®, AstraZeneca, UK). 
 
1.4.4 Gonadotrophin releasing hormone antagonists 
At about the same time as the GnRH agonists were being developed, work was being carried 
out to synthesise the GnRH antagonists. GnRH antagonists result from multiple substitutions 
of amino acids in the native GnRH molecule, and can suppress gonadotrophin secretion by 
competing with GnRH for the receptors on the pituitary gonadotroph cell membranes. 
Administration of the GnRH antagonists produces immediate and transient suppression of the 
secretion of FSH and LH. They lack the initial stimulatory ‘flare effect’ of the agonists. The 
first GnRH antagonist was developed in 1972, by the replacement of the histidine residue at 
position number two. The initial preparations of the GnRH antagonists had side effects such 
as an oedematous reaction caused by the release of histamine from the mast cells (Hahn et al., 
1985), and depot formation after injection due to ‘gelling’ resulting in unreliable and 
unpredictable release. The present (fourth) generation of GnRH antagonists, such as 




Netherlands) used in assisted reproduction, have been developed to overcome these side 
effects.  
 
1.5 Challenges to ovarian stimulation in IVF treatment 
More than five million babies have been born using IVF and other assisted reproductive 
technologies (ART) since the first IVF birth in 1978 and these numbers continue to rise with 
more couples accessing IVF treatment. With its widespread use and acceptance have come 
challenges. An important milestone in IVF treatment was the introduction of COH regimens 
contributing to improved success rates. Research is still being carried out to find the best 
stimulation dose and regimen for individual women, in order to produce an optimal response 
and results without the risk of over- or under-response. There is sustained research to 
individualise COH regimens for women and thereby maximise IVF outcome whilst 
minimising side effects. 
 
The two major challenges which still face COH in IVF treatment are women with polycystic 
ovary syndrome (PCOS), and women who produce a poor response to even very high levels 
of ovarian stimulants. Women with PCOS have a tendency to over respond to gonadotrophin 
stimulation and at a risk of developing ovarian hyperstimulation syndrome (OHSS). Poor 
responders have an inadequate response to gonadotrophin stimulation, which can lead to the 
retrieval of few oocytes or cycle cancellation (Keay et al., 1997). Since the number of oocytes 
retrieved will affect the possible number of embryos available for transfer, it is a major 
influence on the prognosis for the success of IVF treatment (Ulug et al., 2003); poor ovarian 




The aim of my research as laid out in this thesis is a critical examination of the interventions 
developed for poor responders undergoing IVF treatment. There are a range of interventions 
that have been proposed to improve the IVF outcome for poor responders. As the choice of 
the pituitary suppression regimen during COH might influence the outcome of poor 
responders, I set out to systematically review the various COH regimens to perform a meta-
analysis of available data with an aim of finding the ideal pituitary suppression regimen for 
poor responders. The systematic review recognised the need for a well designed randomised 
controlled trial (RCT). The protocol developed for the RCT to determine an ideal COH 
regimen for poor responders undergoing IVF treatment is presented and the process of setting 
up the trial discussed. The study protocol was envisaged to overcome the short comings with 
existing studies on poor responders. The primary outcome for my RCT is number of oocytes 
retrieved reflecting the definition of poor ovarian response. Therefore the relationship 
between the number of oocytes retrieved and live birth rate following IVF is explored to 
establish whether the number of oocytes retrieved could be used as a surrogate outcome in 
IVF research. A prediction model for estimating live birth following IVF based on the 
number of oocytes retrieved and female age is discussed. There is often speculation whether 
there is cycle to cycle variation in women with poor ovarian response and whether having 
IVF in a different cycle influences the outcome. The outcomes of two consecutive IVF cycles 
with the same COH regimen are compared to examine intercycle variability. The results of 
the RCT comparing three COH regimens are discussed and finally, the role of androgens in 
ovarian folliculogenesis and their potential role as adjuvants in poor responders is reviewed 








Controlled ovarian hyperstimulation regimens in 
poor responders undergoing IVF treatment: 








Poor ovarian response to gonadotrophin stimulation in IVF treatment remains a practical 
challenge for clinicians and a source of significant distress for women undergoing assisted 
reproduction. Poor ovarian response, defined as the development of an insufficient number of 
mature follicles following gonadotrophin stimulation leading to cycle cancellation or the 
yield of only a few oocytes, occurs in 9 – 24% of women undergoing IVF treatment (Keay et 
al., 1997), and is an increasing problem as women delay childbearing (Bewley et al., 2005). 
The number of oocytes retrieved and the number of embryos available for transfer influence 
substantially the prognosis for the success of IVF treatment (Ulug et al., 2003). In 
comparison to normal responders, these women have lower pregnancy rates. Several 
interventions and protocols have been proposed in an attempt to improve the outcome in this 
group of women, which include varying the regimen for pituitary suppression and ovarian 
stimulation as well as the use of adjuvant therapies (Shanbhag et al., 2007). 
 
The introduction of GnRH agonists in assisted reproduction played an important role in the 
improvement of IVF treatment success by reducing the incidence of a premature LH surge 
which resulted in fewer cycle cancellations and higher pregnancy rates (Hughes et al., 1992) 
and allowed cycle programming. GnRH antagonists which prevent a premature LH surge by 
their more direct action were subsequently introduced as an alternative to the GnRH agonists 
allowing a shorter duration of treatment. The GnRH antagonists competitively block the 
pituitary receptors and thereby cause immediate suppression of the LH (Klingmuller et al., 
1993). The long GnRH agonist pituitary down regulation combined with exogenous 





There is currently no consistency in the choice of COH regimen for women with poor ovarian 
response undergoing IVF. The choice of COH regimens for the management of poor 
responders is based mainly on the preferences of individual centres or clinicians. A recent 
survey (IVF-Worldwide, 2010) conducted in 196 centres from 45 countries showed a wide 
variation in the GnRH analogue protocols chosen for poor responders (Figure 2.1).  
 
Figure 2.1: Worldwide survey of use of GnRH analogue protocols for poor responders 
 
 
The reasons for this variation in practice are likely to the paucity of robust evidence and 
heterogeneity in the trials with regards to issues such as the definition for poor ovarian 
response and clinical protocols used in individual studies. In an attempt to summarise the 





2.2 Materials and methods 
The following databases, MEDLINE (1950 to June 2010), EMBASE (1980 to June 2010), 
Cochrane Library, Web of Science and National Research Register were searched for 
relevant studies. A combination of Medical Subject Headings (MeSH) and text words were 
used to generate two subsets of citations; one included studies of poor responders (‘poor 
ovarian response’, ‘poor respon*’, ‘low respon*’), and the other, studies of IVF (‘fertilization 
in vitro’, ‘IVF’, ‘intracytoplasmic sperm injection’, and ‘reproductive techniques assisted’). 
These subsets were combined using ‘AND’ to generate a subset of citations relevant to the 
research question. The reference lists of all known primary and review articles were 
examined to identify cited articles not captured by electronic searches. Enquiries were also 
made about unpublished studies from researchers in this field. No language restrictions were 
placed in any of the searches. The searches were conducted independently by two 
individuals, Sesh Kamal Sunkara (SKS) and Arri Coomarasamy (AC). 
 
2.2.1 Study selection and data extraction 
Studies were selected if the target population was mainly women undergoing IVF treatment 
with a history of poor ovarian response in a previous cycle. The interventions were the GnRH 
agonist long regimen, the GnRH agonist short regimen, the GnRH antagonist regimen, the 
GnRH agonist long stop regimen and other modifications of the agonist long regimen. 
Studies were included if they were of randomised design and the primary outcome of interest 
was the clinical pregnancy rate. Secondary outcome measures such as the number of oocytes 
retrieved, number of mature oocytes, cycle cancellation rate, ongoing pregnancy rate and the 




Studies were selected in a two-stage process. Firstly, the titles and abstracts from the 
electronic searches were scrutinized by two reviewers independently (SKS and AC) and full 
manuscripts of all citations that were likely to meet the predefined selection criteria were 
obtained. Secondly, final inclusion or exclusion decisions were made on examination of the 
full manuscripts. In cases of duplicate publication, it was agreed to select the most recent or 
complete versions. Any disagreements about inclusion were resolved by consensus or 
arbitration by a third reviewer, Peter Riven Braude (PRB). 
 
Two reviewers (SKS and AC) completed the data extraction and quality assessment (Berlin et 
al., 1999). Authors of the primary studies were contacted for any missing or unclear 
information. The selected studies were assessed for methodological quality by using the 
components of study design that are related to the internal validity (CRD Report Number 4, 
2001). Information on the adequacy of randomization, allocation concealment, blinding, 
intention to treat (ITT) analysis and follow up rates was sought by examining the full text 
articles and contacting the authors if necessary. Study characteristics such as population 





2.2.2 Pituitary suppression regimens for COH 
The details of the interventions addressed in the systematic review are described below and 
are shown diagrammatically. 
 
GnRH agonist long regimen 
With the long regimen, pituitary desensitisation with the GnRH agonist is commenced in the 
mid-luteal phase of the previous cycle. After confirmation of ovarian quiescence 
approximately two weeks later, gonadotrophin for ovarian stimulation is commenced and 


















GnRH agonist short regimen 
In the short regimen, the GnRH agonist is commenced in the early follicular phase of the 
cycle (day 1 to day 3) followed by gonadotrophin (usually commenced a day later). Both the 





GnRH antagonist regimen 
In the antagonist regimen, ovarian stimulation with gonadotrophin is commenced in the early 
follicular phase. The GnRH antagonist is commenced on day 6 of stimulation or when the 
leading follicle is ≥14mm. Both the gonadotrophin and the GnRH antagonist are continued 





hCG administration Day 1-3 of cycle 








GnRH agonist long stop regimen 
With this regimen pituitary desensitization with the GnRH agonist is commenced in the mid-
luteal phase of the previous cycle. After confirmation of ovarian quiescence, gonadotrophin 
for ovarian stimulation is commenced and continued until the administration of hCG. GnRH 






Modified agonist long regimen 
With the modified agonist long regimen, gonadotrophin stimulation is commenced in the 

















2.2.3 Statistical analysis 
From each study outcome data were extracted in 2x2 tables (for discrete variables) or as 
means or medians with a measure of variance (such as standard deviation) for continuous 
variables. For discrete variables, relative risks were pooled using fixed (Mantel and Haenszel, 
1959) and random effects (DerSimonian and Laird, 1986) models, if significant heterogeneity 
could be excluded. Weighted mean difference (WMD) was calculated for continuous 
variables using means and standard deviations (SD) from individual studies. Heterogeneity of 
treatment effects was evaluated graphically using forest plot (Lewis and Clarke 2001) and 
statistically using the I2 statistic (Higgins and Thompson 2002). Exploration of clinical 
heterogeneity was planned using variation in features of the population, intervention, 




2.3.1 Study selection process 
The search strategy yielded 594 citations, captured from electronic citations and examination 
of the reference lists of the primary and review articles. Five hundred and sixty eight 
publications were excluded as it was clear from the title and abstract that they did not fulfil 
the selection criteria. Full manuscripts were obtained for the remaining 26 articles. Following 
scrutiny of the full manuscripts, two studies were excluded as the study design was 
inappropriate for analysis since women had been analysed more than once (Dirnfeld et al., 
1999; Morgia et al., 2004) and three studies were excluded as they involved only women with 




ovarian response in a previous IVF treatment cycle (De Placido et al., 2006; Devasa R. de la 
Rua et al., 2008; Kim et al., 2009). Twenty-one studies, therefore, met the selection criteria 
for the review (Figure 2.2). 
 
Figure 2.2: Study selection process for systematic review of controlled ovarian 















Citations excluded after screening 
titles and/ or abstracts: n = 568 
Total number of citations retrieved from electronic searches and from 
examination of reference lists of primary and review articles: n = 594 
Primary articles included in systematic review: n = 21 
Full manuscripts retrieved for detailed evaluation: n = 26 
Articles excluded with reasons: 
• Inappropriate study design, more 
than one cycle analysed per 
woman:  n=2 
• Studies involving presumed poor 





In the 21 included studies, women were randomized to the GnRH agonist long regimen, the 
GnRH agonist short regimen, the GnRH antagonist regimen, the GnRH agonist long stop 
regimen or another modification of the GnRH agonist long regimen. Of the 21 RCTs, two 
studies involved the GnRH agonist long regimen versus the GnRH agonist short regimen 
(Dirnfeld et al., 1991; Weissman et al., 2003), nine studies involved the GnRH agonist short 
versus the GnRH antagonist regimen (Akman et., 2001; Marci et al., 2003; Malmusi et al., 
2005; Schmidt et al., 2005; Mohamed et al., 2006; Aletebi et al., 2007; Lainas et al., 2008; 
Demirol et al., 2009; Kahraman et al., 2009) and four studies involved the GnRH agonist 
long versus the GnRH antagonist regimen (Cheung et al., 2005; Marci et al., 2005; Tazegul et 
al., 2008; Tehraninejad et al., 2009). Two studies involved the GnRH agonist long stop 
versus the GnRH agonist long regimen (Garcia-Velasco et al., 2000; Tehraninejad et al., 
2008). There were one study each involving the modified GnRH agonist long regimen versus 
the standard GnRH agonist long regimen (Kucuk et al., 2008), the modified GnRH agonist 
long regimen versus the GnRH agonist short regimen (Kucuk et al., 2007), the GnRH 
antagonist regimen versus no down regulation (Akman et al., 2000) and the GnRH antagonist 
versus a modified GnRH antagonist regimen (Kalra et al., 2008). 
 
2.3.2 Quality and characteristics of included studies 
The quality of the 21 included trials was generally poor. There was no evidence of allocation 
concealment in 14 of the 21 studies, six did not follow intention to treat (ITT) analysis and 
only three studies had blinding of the assessors. There was clinical heterogeneity among 
studies in their definition of poor ovarian response and thus their inclusion and exclusion 
criteria. The quality and the main characteristics of the included studies are presented in 




Table 2.1: Quality of studies included in the review of controlled ovarian hyperstimulation regimens in poor responders 










Method of randomisation – table of 
random numbers; Allocation 
concealment - unreported 
Unreported Yes > 95% No data 
Akman, 2000 
Method of randomisation – consecutive 
number method; Allocation 
concealment - unreported 
Unreported Yes > 95% > 95% 
Garcia-
Velasco, 2000 
Method of randomisation – computer 
generated list; Allocation concealment 
by opaque sealed envelopes 
Unreported Yes > 95% No data 
Akman, 2001 
Method of randomisation - unclear; 
Allocation concealment - unreported 
Unreported Yes > 95% > 95% 
Marci, 2003 
Method of randomisation - unclear; 
Allocation concealment - unreported 





Method of randomisation – computer-
generated list; Allocation concealment - 
unreported 




Table 2.1 continued 












Method of randomisation – computer-
generated list; Adequate concealment 
by opaque envelopes  
Single 
blinded 
No > 95% > 95% 
Malmusi, 
2005 
Method of randomisation - unclear; 
Allocation concealment - unreported  
Unreported No > 95% No data 
Marci, 2005 
Method of randomisation – by a 
randomization list; Allocation 
concealment - unreported  
Unreported Yes > 95% > 95% 
Schmidt, 2005 
Method of randomisation – computer-
generated list; Adequate concealment 
by sealed envelopes 
Unreported No > 95% > 95% 
Mohamed, 
2006 
Method of randomisation - unclear; 
Adequate concealment by opaque 
envelopes 
Unreported No No data No data 
Aletebi, 2007 
Method of randomisation - unclear; 
Adequate concealment by opaque 
envelopes 




Table 2.1 continued 












Method of randomisation – consecutive 
number method; Allocation 
concealment - unreported 
Unreported Yes > 95% No data 
Kalra, 2008 
Method of randomisation – computer-
generated list; Adequate concealment 
by sealed envelopes 
Unreported Yes > 95% > 95% 
Kucuk, 2008 
Method of randomisation - unclear; 
Allocation concealment - unreported 
Unreported No > 95% No data 
Lainas, 2008 
Method of randomisation – computer-
generated list; Allocation concealment - 
unreported 
No Yes > 95% > 95% 
Tazegul, 2008 
Method of randomisation – computer-
generated list; No allocation 
concealment  







Table 2.1 continued 













Method of randomisation - unclear; 
Allocation concealment - unreported 
Unreported Yes > 95% No data 
Demirol, 2009 
Method of randomisation – computer 
generated list; Allocation concealment 
by  opaque sealed envelopes 
Single 
blinded 
Yes > 95% No data 
Kahraman, 
2009 
Method of randomisation – consecutive 
number method; Allocation 
concealment - unreported 
No Yes > 95% No data 
Tehraninejad, 
2009 
Method of randomisation – computer 












Table 2.2: Characteristics of studies included in the review of controlled hyperstimulation regimens in poor responders 
 




Women who had at least one 
previous unsuccessful attempt 
at ovarian stimulation with an 
inadequate response or 
cancellation of oocyte retrieval 
N=28 
GnRH agonist long 
regimen 
N=26 
GnRH agonist short 
regimen 
Cancelled cycles  
Duration of stimulation  
Total gonadotrophin dose 
Number of  oocytes retrieved  
Clinical pregnancies 
Akman, 2000 N=40 
Women who had at least two 
previous IVF cycles with poor 
response due to one of the 
following reasons:  
Serum basal FSH > 15 IU/l, 
serum (oestradiol) E2 level < 
500pg/ml on day of hCG or < 








Cancelled cycles  
Number of  mature oocytes 







Table 2.2 continued 




Women who had at least one 
previous IVF cycle cancelled 
due to ≤ 3 follicles ≥ 18 mm in 
diameter and serum basal FSH 
< 12 IU/l 
N=36 
GnRH agonist long 
regimen 
N=34 
GnRH agonist stop 
regimen 
Cancelled cycles 
Duration of stimulation 
Total gonadotrophin dose 
Number of oocytes retrieved 
Number of  mature oocytes 
Number of embryos transferred 
Clinical pregnancies 
Akman, 2001 N=48 
Women who had at least two 
failed IVF cycles with poor 
response due to one of the 
following reasons:  
Serum basal FSH > 15 IU/l, 
serum E2 level < 500pg/ml on 
day of hCG or < 4 mature 
oocytes retrieved 
N=24 






Total gonadotrophin dose 
Number of oocytes retrieved 
Number of mature oocytes 
Number of embryos transferred 






Table 2.2 continued 
Study Participants Intervention Groups Outcomes 
Marci, 2003 N=38 
Women with a poor ovarian 
response in a previous standard 
treatment 
N=19 






Duration of stimulation 
Total gonadotrophin dose 





Women with poor ovarian 
response in a previous IVF 
cycle. Poor response defined as 
< 5 oocytes, ≤ 3 follicles ≥16 
mm on day of cycle 
cancellation or serum E2 < 500 
pg/ml on day of hCG. Only 
women with serum basal FSH 
< 20 IU/l were included 
Prior stimulation regimens 




agonist short regimen 
N=31 
Modified GnRH 
agonist long regimen 
Cancelled cycles 
Duration of stimulation 
Total gonadotrophin dose 
Number of oocytes retrieved 






Table 2.2 continued 
Study Participants Intervention Groups Outcomes 
Cheung, 2005 N=66 (initially recruited) 
Women with poor ovarian 
response in a previous IVF 
cycle with < 3 mature follicles 
on a long agonist regimen or 
poor responders defined as 
women with repeated high 
basal levels of FSH > 10 IU/l. 
N=32 






Duration of stimulation 
Total gonadotrophin dose 
Number of oocytes retrieved 
Number of mature oocytes  




N=55 (60 initially recruited) 
Women with poor ovarian 
response in a previous IVF 
cycle. Poor response defined as 
no ovarian response or < 5 
oocytes retrieved when ≥ 300 
IU/day of FSH administered 
for ≥ 15days. All women had 
serum basal FSH < 15 IU/l at 
the previous IVF attempt 
N=30 






Duration of stimulation 
Number of oocytes retrieved 
Number of mature oocytes 






Table 2.2 continued 
Study Participants Intervention Groups Outcomes 
Marci, 2005 N=60 
Women with poor ovarian 
response in a previous IVF 
cycle. Poor response defined as 
serum E2 level < 600pg/ml on 
day of hCG and < 3 oocytes 
retrieved after a previous 
standard long protocol using 
recombinant gonadotrophin 
dose of 225 IU/day for 
stimulation. 
N=30 






Duration of stimulation 
Total gonadotrophin dose 
Number of oocytes retrieved 





N=48 (initially recruited)  
Women with poor ovarian 
response in previous IVF cycle 
with a gonadotrophin dose of 
300 IU/day. Poor response 
defined as peak serum E2 level 
≤ 850pg/ml or ≤ 4 follicles ≥ 
15mm on day of hCG. All 
women had basal FSH < 13 
IU/l and E2 < 75pg/ml. 
N=11 
The microdose GnRH 




Cancelled cycles  
Duration of stimulation 
Number of oocytes retrieved  
Number of mature oocytes 





Table 2.2 continued 
Study Participants Intervention Groups Outcomes 
Mohamed, 
2006 
N=30 (initially recruited) 
Women with poor ovarian 
response in previous IVF 
cycles. Poor response defined 
as < 6 follicles > 12mm in a 
previous cycle with a standard 
agonist long regimen. 
N=15 






Duration of stimulation 
Total gonadotrophin dose 
Number of oocytes retrieved 
 
 
Aletebi, 2007 N=43 
Women with poor ovarian 
response in previous IVF 
cycles. Poor response defined 
as < 5 oocytes retrieved 
following stimulation for ≥ 15 
days in women with basal FSH 
< 15 IU/l. 
Prior stimulation regimens 
involved 300 IU of 
gonadotrophin daily. 
N=20 






Cancelled cycles  
Total gonadotrophin dose  
Number of  mature oocytes 






Table 2.2 continued 
Study Participants Intervention Groups Outcomes 
Kucuk, 2007 N=42 
Women with poor ovarian 
response in previous IVF 
cycles. Poor response defined 
as < 4 oocytes retrieved. All 
women had a serum basal FSH 
< 15 IU/l 
N=21 
Modified GnRH 
agonist long regimen 
N=21 
GnRH agonist short 
regimen 
Cancelled cycles  
Duration of stimulation 
Total gonadotrophin dose  
Number of  mature oocytes  
Number of embryos transferred  
Clinical pregnancies 
 
Kalra, 2008 N=18 
Women with poor ovarian 
response in previous IVF 
cycles. Poor response defined 
as previous cycle cancellation, 
< 5 follicles on day of hCG or 








Duration of stimulation 
Total gonadotrophin dose 
Number of  oocytes retrieved 







Table 2.2 continued 
Study Participants Intervention Groups Outcomes 
Kucuk, 2008 N=42 (initially recruited), 40 
analysed 
Women with poor ovarian 
response in previous IVF 
cycles. Poor response defined 
as < 4 oocytes retrieved. All 
women had a serum basal FSH 




agonist long regimen 
N=19 
GnRH agonist long 
regimen 
Cancelled cycles 
Total gonadotrophin dose 
Number of embryos transferred 
Clinical pregnancies 
Lainas, 2008 N=270 
Women with poor ovarian 
response in previous IVF 
cycles. Poor response defined 
as < 5 oocytes retrieved 
Prior stimulation regimens 
involved ≥ 300 IU of 
gonadotrophin daily 
N=90 






Duration of stimulation 
Number of oocytes retrieved 
Number of  mature oocytes 







Table 2.2 continued 
Study Participants Intervention Groups Outcomes 
Tazegul, 2008 N=96 (initially recruited) 
Women with poor ovarian 
response in previous IVF 
cycles. Poor response defined 
as peak serum E2 level ≤ 500 
pg/ml, ≤ 3 mature follicles > 
16mm on day of hCG or <3 
oocytes retrieved. All women 
had serum basal FSH < 13 IU/l 
N=45 
The minidose GnRH 




 Cancelled cycles 
Duration of stimulation 
Total gonadotrophin dose  
Number of oocytes retrieved  






Women with at least one 
previous cancelled IVF cycle. 
Poor response defined as < 3 
follicles > 18 mm in women 
with serum basal FSH < 12 
IU/l 
N=20 
GnRH agonist long 
regimen 
N=20 
GnRH agonist stop 
regimen 
Cancelled cycles  
Duration of stimulation 
Total gonadotrophin dose 
Number of oocytes retrieved  
Number of  mature oocytes 






Table 2.2 continued 
Study Participants Intervention Groups Outcomes 
Demirol, 2009 N=90 
Women with poor ovarian 
response in a minimum of two 
previous IVF cycles. Poor 
response defined as peak 
serum E2 level < 500 pg/ml or 
<4 mature oocytes retrieved. 
All women had a serum basal 
FSH > 15 IU/l 
N=45 
The microdose GnRH 





Duration of stimulation 
Total gonadotrophin dose 
Number of  mature oocytes 





Women with poor ovarian 
response in previous IVF 
cycles. Poor response defined 
as peak serum E2 level < 500 
pg/ml on day of hCG, < 4 
mature oocytes retrieved or 
previous cancelled cycle. 
Prior stimulation regimens 
involved gonadotrophin dose 
of 150 or 225 IU daily 
N=21 
The microdose GnRH 





Duration of stimulation 
Total gonadotrophin dose 
Number of oocytes retrieved 
Number of  mature oocytes 





Table 2.2 continued 




Women with poor ovarian 
response in previous IVF 
cycle. Poor response defined as 
peak serum E2 level < 500 
pg/ml on day of hCG, < 3 
mature oocytes retrieved, 
previous cancelled cycle or 
women with repeated high 
serum basal FSH levels of > 15 
IU/l or a total antral follicle 
count of < 3 
N= 35 





Cancelled cycles  
Duration of stimulation 
Total gonadotrophin dose  
Number of oocytes retrieved  
Number of  mature oocytes 
retrieved  







2.3.3 Study outcomes 
Primary outcome 
Clinical pregnancy rate 
GnRH agonist long versus GnRH agonist short regimen 
Meta-analysis of the two studies (Dirnfeld et al., 1991; Weissman et al., 2003) that compared 
the agonist long regimen versus the agonist short regimen showed a significantly higher 
clinical pregnancy rate with the agonist long regimen compared to the agonist short regimen 
(RR: 4.66; 95% CI: 1.43, 15.17; P = 0.01, Figure 2.3). The I2 value was 0% indicating 
statistical homogeneity between the studies. 
 
GnRH agonist short versus GnRH antagonist regimen 
Eight studies (Akman et ., 2001; Marci et al., 2003; Malmusi et al., 2005; Schmidt et al., 
2005; Aletebi et al., 2007; Lainas et al., 2008; Demirol et al., 2009; Kahraman et al., 2009) 
out of the nine that compared the agonist short with the antagonist regimens reported clinical 
pregnancy as an outcome. Meta-analysis of these studies showed no significant difference in 
the clinical pregnancy rate between the two regimens (RR: 0.94; 95% CI: 0.63, 1.39; P = 
0.75, Figure 2.3). The I2 value was 8.4% indicating statistical homogeneity across the studies. 
 
GnRH agonist long versus GnRH antagonist regimen 
Meta-analysis of the four studies (Cheung et al., 2005; Marci et al., 2005; Tazegul et al., 




regimen showed no significant difference in the clinical pregnancy rate between the two 
regimens (RR: 0.85; 95% CI: 0.53, 1.37; P = 0.51, Figure 2.3). The I2 value was 0% 
indicating statistical homogeneity between the studies. 
 
GnRH agonist stop versus GnRH agonist long regimen 
Meta-analysis of the two studies (Garcia-Velasco et al., 2000; Tehraninejad et al., 2008) that 
compared the agonist stop regimen with the agonist long regimen showed no significant 
difference in the clinical pregnancy rate between the two regimens (RR: 1.74; 95% CI: 0.67, 




One study each compared the modified agonist long regimen with the standard agonist long 
regimen (Kucuk et al., 2008) and the agonist short regimen (Kucuk et al., 2007). These 
studies did not show any significant difference in clinical pregnancy rates between the 
respective comparisons (RR = 4.00; 95% CI: 0.96, 16.66; P = 0.06 and RR = 2.67; 95% CI: 
O.82, 8.69; P = 0.10, Table 2.3). 
 
One study compared the modified antagonist regimen involving luteal phase start of 
gonadotrophins and administration of the GnRH antagonist with the lead follicle ≥ 14 mm 
versus the standard antagonist regimen involving start of gonadotrophin on cycle day one or 




showed no significant difference in the clinical pregnancy rate between the two comparison 
groups (RR = 0.33; 95% CI: 0.04, 2.63; P = 0.30, Table 2.3). One study that compared the 
antagonist regimen with no GnRH analogue administration (Akman et al., 2000) also showed 
no significant difference in the clinical pregnancy rate (RR = 3.00; 95% CI: 0.34, 26.45; P = 
0.32, Table 2.3). 
 
Secondary outcomes 
Number of oocytes and mature oocytes retrieved 
GnRH agonist long versus GnRH agonist short regimen 
Meta-analysis of the two studies (Dirnfeld et al., 1991; Weissman et al., 2003) that compared 
the agonist long regimen versus the agonist short regimen showed the number of oocytes 
retrieved to be significantly higher with the agonist long regimen (WMD: 1.36; 95% CI: 0.30, 
2.43; P = 0.01, Figure 2.4). Neither of the two studies reported the number of mature oocytes 
as an outcome. 
 
GnRH agonist short versus GnRH antagonist regimen 
Meta-analysis of the four studies (Akman et al., 2001; Malmusi et al., 2005; Schmidt et al., 
2005; Kahraman et al., 2009) out of the nine that compared agonist short versus antagonist 
regimen and reported the number of oocytes as an outcome showed the number of oocytes 
retrieved to be significantly higher with the agonist short regimen (WMD: 0.55; 95% CI: 





Meta-analysis of the five studies (Malmusi et al., 2005; Schmidt et al., 2005; Aletebi et al., 
2007; Demirol et al., 2009; Kahraman et al., 2009) out of the nine that compared the agonist 
short versus the antagonist regimen and reported the number of mature oocytes as an outcome 
however showed no significant difference between the two regimens (WMD: 0.37; 95% CI: - 
0.45, 1.20; P = 0.37, Table 2.3). 
 
GnRH agonist long versus GnRH antagonist regimen 
Meta-analysis of the four studies (Cheung et al., 2005; Marci et al., 2005; Tazegul et al., 
2008; Tehraninejad et al., 2009) that compared the agonist long regimen with the antagonist 
regimen showed no significant difference in the number of oocytes retrieved between the two 
regimens (WMD: - 0.15; 95% CI: - 1.17, 0.88; P = 0.78, Figure 2.4).  
 
Meta-analysis of the two studies (Cheung et al., 2005; Tehraninejad et al., 2009) that reported 
the number of mature oocytes as an outcome also showed no significant difference between 
the two regimens (WMD: 0.38; 95% CI: - 0.59, 1.35; P = 0.44, Table 2.3). 
 
GnRH agonist stop versus GnRH agonist long regimen 
Meta-analysis of the two studies (Garcia-Velasco et al., 2000; Tehraninejad et al., 2008) that 
compared the agonist stop regimen with the agonist long regimen showed the number of 
oocytes and the number of mature oocytes retrieved to be significantly higher with the 
agonist stop regimen (WMD: 2.42; 95% CI: 2.06, 2.77; P < 0.00001, Fig 2.4 and WMD: 2. 





The number of oocytes retrieved was significantly higher with the modified long regimen 
compared to the standard agonist long regimen (WMD= 3.54; 95% CI: 2.54, 4.54, P < 
0.00001, Table 2.3) and with the modified long regimen compared to the agonist short 
regimen (WMD= 2.94; 95% CI: 1.91, 3.97, P < 0.00001, Table 2.3). There was no significant 
difference in the number of mature oocytes retrieved with the antagonist regimen when 
compared to the regimen without any GnRH analogue administration (WMD= - 0.21; 95% 
CI: - 0.48, 0.06, P = 0.13, Table 2.3). 
 
Cancelled cycles 
The cycle cancellation rate was significantly lower with the agonist long compared to the 
agonist short regimen (RR = 0.23; 95% CI: 0.07, 0.77; P = 0.02, Table 2.3). No significant 
differences were noted for cycle cancellation rate for the other comparisons (Table 2.3). 
 
Ongoing pregnancy rate 
Only eight studies reported ongoing pregnancy as an outcome (Akman et al., 2000; Akman et 
al., 2001; Cheung et al., 2005; Marci et al., 2005; Kalra et al., 2008; Lainas et al., 2008; 
Tazegul et al., 2008; Tehraninejad et al., 2009). Pooling of results showed no significant 





Duration of gonadotrophin stimulation 
No significant differences were noted for the outcome of the duration of gonadotrophin 
stimulation for the comparisons agonist long versus agonist short, agonist short versus 
antagonist and agonist long versus antagonist regimens (Table 2.3). The duration of 
gonadotrophin stimulation was significantly lower with the agonist stop regimen compared to 
the agonist long regimen (WMD= - 1.21; 95% CI: - 1.42, - 1.00, P < 0.00001, Table 2.3). The 
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CI: 0.30, 2.43 
 RR = 0.23; 
95% CI: 
0.07, 0.77 
- WMD = 1.20; 
95% CI: - 0.77, 
3.17 
WMD = 4.10; 





RR = 0.94; 




CI: 0.14, 0.96 
WMD = 0.37; 
95% CI:          
- 0.45, 1.20 
RR = 0.97; 
95% CI: 
0.72, 1.32 
RR = 0.64; 
95% CI: 
0.18, 2.30 
WMD =  0.05; 
95% CI: - 0.28, 
0.37 
WMD = - 11.16; 





RR = 0.85; 
95% CI: 0.53, 
1.37 
WMD =         
- 0.15; 95% 
CI: - 1.17, 
0.88 
WMD = 0.38; 
95% CI:                
- 0.59, 1.35 
RR = 0.98; 
95% CI: 
0.56, 1.71 
RR = 0.78; 
95% CI: 
0.45, 1.37 
WMD =  1.87; 
95% CI: - 0.69, 
4.42 
WMD =  10.64; 





RR = 1.74; 




CI: 2.06, 2.77 
WMD = 2.20; 
95% CI: 0.89, 
3.52 
RR = 1.03; 
95% CI: 
0.19, 5.72 
- WMD = - 1.21; 
95% CI: - 1.42,      
- 1.00 
WMD = - 11.24; 
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95% CI: 0.96, 
16.66 
WMD  = 
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CI: 2.54, 4.54 
- RR = 0.18; 
95% CI: 
0.01, 3.56 
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RR = 2.67; 
95% CI: 0.82, 
8.69 
WMD  = 
2.94; 95% 
CI: 1.91, 3.97 
- RR = 0.20; 
95% CI: 
0.01, 3.93 








RR = 3.00; 
95% CI: 0.34, 
26.45 
- WMD - 0.21; 
95% CI:             
- 0.48, 0.06 
RR = 1.00; 
95% CI: 
0.23, 4.37 
RR = 1.00; 
95% CI: 
0.23, 4.37 
- WMD = - 3.56; 






RR = 0.33; 
95%CI: 0.04, 
2.63 
- - RR = 0.33; 
95% CI: 
0.02, 7.24 
*RR = 0.20; 
95% CI:  
0.01, 3.66 
- - 




 2.4 Discussion 
The GnRH analogues were introduced during COH for IVF to overcome two problems; 
occurrence of a premature LH surge and the effects of tonic hypersecretion of LH in the 
follicular phase. Premature luteinisation results in cycle cancellation in up to 15% of cases 
(Lunenfeld et al., 1997). The introduction of pre treatment by down regulation with GnRH 
agonists reduced the rate of cycle cancellation due to a premature LH surge to less than 2% 
and increased the effectiveness of IVF treatment with higher pregnancy rates (Schmutzler and 
Diedrich, 1990). 
 
The GnRH agonist short regimens were suggested in an attempt to improve cycle outcome in 
poor responders by avoiding the excessive pituitary suppression with the agonist long 
regimens, while taking advantage of the additional gonadotrophin stimulation provided by the 
initial flare effect of the GnRH agonist (Garcia et al., 1990). The GnRH antagonist regimens 
were introduced with the aim of avoiding the profound suppression of endogenous FSH and 
LH concentrations in the early follicular phase at the stage follicular recruitment, as they can 
be commenced later because of their more immediate action (Kenigsberg et al., 1984). Due to 
evidence of extrapituitary effects of GnRH agonists on the ovary where GnRH receptors were 
localised (Latouche et al., 1989), it appeared that GnRH agonists may inhibit ovarian 
responsiveness to gonadotrophins (Kowalik et al., 1998). With the GnRH agonist stop 
regimen the GnRH agonist is stopped once pituitary down regulation is established and 





 Following our previous published review on pituitary suppression regimens in poor 
responders undergoing IVF treatment (Sunkara et al., 2007) several new randomised 
controlled trials (RCTs) have emerged on interventions for poor responders. The Cochrane 
review (Pandian et al., 2010) involving only those studies where women had a poor response 
in a previous agonist long regimen included 10 RCTs and found insufficient evidence to 
support any particular regimen. 
 
In this systematic review involving 21 RCTs, the effectiveness of the various down regulation 
regimens in women with poor ovarian response in a previous IVF ± ICSI cycle undergoing a 
subsequent treatment cycle was evaluated. There were important differences in the inclusion 
and exclusion criteria between my review and the Cochrane review (Pandian et al., 2010), 
resulting in a difference in the selection of studies. The Cochrane review included only those 
studies where women had the GnRH agonist long regimen in the previous cycle that had a 
poor ovarian response. As there is variation among the choice of COH regimen for women 
undergoing IVF treatments worldwide and with current lack of evidence that any regimen is 
particularly better in poor responders, we chose to include women who had a poor ovarian 
response in the previous cycle irrespective of the COH regimen. In addition further studies 
have been published since the Cochrane review and have been included in my review. 
In my review, which involved 1142 IVF ± ICSI cycles in poor responders, there was no 
significant difference in the clinical pregnancy rate among the various down regulation 
regimens compared, apart from the GnRH agonist long regimen which was shown to be 
significantly better than the GnRH agonist short regimen (Figure 2.4). There was 
inconsistency in the results for the outcome of number of oocytes and number of mature 
oocytes retrieved among the various comparisons rendering it impossible to make any 
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 conclusions. No significant difference was noted among the various comparisons for the 
outcome of ongoing pregnancy rate. It was demonstrated that there is insufficient evidence to 
suggest any one COH regimen is associated with improved cycle outcomes. The validity of 
this finding depends on the methodological rigour of the review and the component primary 
studies. A prospective protocol was used, and a concerted effort made to find all the 
evidence. 
 
A major problem usually encountered when synthesizing the evidence in meta-analyses is 
clinical and methodological heterogeneity between the studies. A recurring difficulty 
encountered in my review was the differences between the studies in the populations they 
evaluated (definition of poor ovarian response, Table 2.2), which could be a factor 
contributing to the inconsistency in the results. In some studies, poor response was diagnosed 
on the basis of peak oestradiol levels on the day of hCG administration. However, it has been 
shown that the number of oocytes retrieved is a better prognostic parameter than the 
oestradiol levels in predicting IVF treatment outcome (Dor et al., 1992). The lack of a 
uniform definition of poor response makes it difficult to compare treatment outcomes or, 
indeed, develop and assess protocols for prevention and management (Surrey and 
Schoolcraft, 2000). Definitions of poor response should include the degree of ovarian 
stimulation used, as low oocyte numbers (< 4 oocytes) is only detrimental if the cumulative 
dose of gonadotrophins used for ovarian stimulation is >3000 IU and cycle cancellation at 
>300 IU gonadotrophin/ day is associated with a significantly worse prognosis compared to 
cycle cancellation at < 300 IU gonadotrophin/ day (Kailasam et al., 2004). None of the 




 Because of the inconsistent and inconclusive findings for reasons mentioned and the inability 
to determine the ideal regimen for poor responders undergoing IVF treatment, a well 
designed, adequately powered, three arm RCT comparing the efficacy of the GnRH agonist 
long regimen versus the GnRH agonist short regimen versus the GnRH antagonist regimen in 









A randomised controlled trial comparing GnRH 
agonist long regimen versus GnRH agonist short 
regimen versus GnRH antagonist regimen in women 








 3.1 Background  
Delayed childbearing in women has been one of the most significant demographic trends in 
western countries (te Velde 1998). A consequence of this has been increasing numbers of 
older women seeking assisted reproduction, and an increasing incidence of poor response to 
ovarian stimulation during IVF treatment. A recent international survey involving 196 IVF 
centres in 45 countries reported an increase in the burden of poor ovarian response over the 
last decade (IVF-Worldwide, 2010). Poor ovarian response results in substantial emotional 
and financial burden on couples and service providers. Potential solutions to poor ovarian 
response are egg donation and adoption. Many couples find these solutions unacceptable. 
Moreover, there is a shortage of gamete donors in the UK, especially since removal of 
gamete donor anonymity in April 2005 (Gudipati et al., 2011). 
 
IVF clinicians are faced with the need to identify treatment strategies that optimise treatment 
outcome for this group of women. One treatment strategy that is commonly thought to 
influence IVF outcome is the choice of the COH regimen (i.e. the pituitary suppression 
regimen). However, there is no consensus on the relative merits of the various COH regimens 
for poor responders, and currently the choice amongst them is generally attributable to a 
clinician’s or a unit’s preference (IVF-Worldwide, 2010). Of the various available COH 
regimens, the three commonly used are: 
• The GnRH agonist long regimen, 
• The GnRH agonist short regimen and  




 The systematic review and meta-analysis on COH regimens in poor responders undergoing 
IVF treatment (Chapter 2) found the evidence to be inconsistent and inconclusive to ascertain 
a best regimen and suggests the need for a well designed RCT comparing the above three 
COH regimens. The extensive search strategy for the systematic review did not identify any 
published trials comparing the three COH regimens in poor responders. A three arm 
randomised controlled trial comparing the GnRH agonist long regimen versus the GnRH 
agonist short regimen versus the GnRH antagonist regimen in poor responders undergoing 
IVF treatment was therefore set up at the Assisted Conception Unit (ACU), Guy’s and St 
Thomas’ Foundation Trust, London and the Lister Fertility Clinic, London and given the 
acronym PRINT: poor responders intervention trial. 
 
3.2 Objective  
The purpose of the trial was to evaluate which of the three commonly used pituitary 
suppression regimens is the most effective for women identified as poor responders based on 
the response to stimulation in their previous IVF treatment cycle. 
 
3.3 Design 
A prospective, allocation-concealed, assessor-blind, three-arm randomised-controlled-trial 
was set up to address the above objective. 
 
3.3.1 Primary outcome 
• The primary outcome is the number of oocytes retrieved 
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 3.3.2 Secondary outcomes 
• The secondary outcomes are the total dose of gonadotrophin (FSH) used for ovarian 
stimulation 
• Number of cycles cancelled before oocyte retrieval 
• Number of mature oocytes retrieved 
• Fertilisation rate 
• Number of cycles reaching embryo transfer 
• Clinical pregnancy rate and 
• Ongoing pregnancy rate 
 
3.3.3 Inclusion criteria 
Any woman undergoing an IVF treatment cycle with or without ICSI who fits the criteria for 
a "poor responder" was eligible to participate in the trial. A "poor responder" was defined as a 
woman who had a previous IVF treatment cycle in which she was stimulated with a daily 
dose of gonadotrophin (FSH) of 300 I.U. or more and  
• Had ≤ 3 oocytes retrieved OR 
• Produced an inadequate number of mature follicles (≤ 3 follicles measuring ≥ 17mm) 
leading to cycle cancellation 
 
3.3.4 Exclusion criteria 
• Women over 40 years of age and 
• Women with a single ovary were not eligible to participate in the study. 
81 
 
 3.3.5 Randomisation 
Third party, distant, internet-based block randomisation with minimisation was employed to 
ensure complete allocation concealment. The aim of minimisation was to balance for 
prognostic variables (age, body mass index (BMI), previous pregnancies and previous live 
births) in the three groups to which women were randomised. Women were randomised into 
the study by internet randomisation at www.medscinet.com/print 
 
3.3.6 Blinding 
PRINT is a single-blinded study, where the assessors (the doctor performing the egg 
collection procedure and the embryologist involved in identifying and assessing the eggs) 
were blinded to the regimen. 
 
3.4 Methods 
All women who had a poor ovarian response in a previous IVF treatment cycle, who were 
advised the option and wished to undertake another IVF treatment cycle were invited to 
participate in the trial. The trial was explained to the woman by a doctor at the clinic 
appointment. A trial participant information sheet (Appendix 1: Participant information 
sheet) explaining the trial was given which had a contact number to speak to the trial 
investigators. The decision of the woman to participate in the trial was entirely voluntary. If 
the woman agreed to participate in the trial she was referred to the trial investigator SKS. The 
woman was requested to sign a consent form (Appendix 2: Trial consent form) and was then 
randomised to one of the three trial regimens by SKS. The woman was informed as to which 
regimen she had been randomised. If the woman needed more time to decide, the clinic 
doctor gained verbal permission for SKS to call and ascertain whether she wished to enrol on 
the trial. If the woman wished to enrol, an appointment was made to sign the trial consent 
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 form. If the woman declined to participate then no further action was required with regard to 
the trial and the woman received standard care. The flowchart in Figure 3.1 describes the 
participant flow in the trial. Details of all participants and outcomes were recorded on the 
case report form (Appendix 3: Trial case report form). 
Figure 3.1: Trial participant flow chart 
Figure 3.1: Participant flow through the PRINT study 
 
Clinic appointment 
PRINT eligibility criteria 
Not eligible Eligible 
Standard care 
Does not agree to 
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participant information 
sheet, invite subject to 
participate in the trial 
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Pregnancy test: urinary or 






 3.4.1 Trial interventions 
The three trial interventions were the (A) GnRH agonist long regimen, (B) the GnRH agonist 
short regimen and (C) the GnRH antagonist regimen. 
 
GnRH agonist long regimen 
With the GnRH agonist long regimen pituitary down-regulation with GnRH agonist, nafarelin 
(Synarel®; Pharmacia, UK) was commenced in the mid luteal phase of the menstrual cycle. 
Nafarelin nasal spray was taken at a dose of two sniffs, twice a day, where one sniff equals 
200 micrograms. Menstruation usually follows within two weeks of starting nafarelin when 
the woman attended the clinic for a transvaginal ultrasound scan to confirm pituitary down 
regulation (quiescent ovaries with follicles ≤ 10mm diameter and endometrium ≤ 5mm in 
thickness). The total antral follicle count (AFC) was measured in both ovaries at the time of 
the down regulation scan. On confirmation of down regulation, ovarian stimulation was 
commenced with FSH, follitropin α (Gonal−F®; Merck-Serono, UK) or hMG (Menopur®; 
Ferring UK) at a dose of 450 IU daily by subcutaneous injection. The dose of the nafarelin 
nasal spray was halved (one sniff, twice a day) during ovarian stimulation. A transvaginal 
ultrasound scan was performed nine days after starting ovarian stimulation and subsequent 
scans if necessary, to assess follicular recruitment and growth. The woman was instructed to 
administer hCG injection subcutaneously when the criteria for triggering ovulation was met. 
FSH and nafarelin were continued until hCG administration. The trial intervention GnRH 




 GnRH agonist short regimen  
With the GnRH agonist short regimen treatment was started on day 2 or 3 of the menstrual 
cycle after a transvaginal ultrasound scan confirming quiescent ovaries and a thin 
endometrium (≤ 5mm endometrial thickness). The total AFC was measured in both ovaries at 
the time of this scan. Nafarelin nasal spray (one sniff twice a day, where each sniff equals 
200 micrograms) was commenced on the 2nd or 3rd day of the menstrual cycle following the 
ultrasound scan. On the 3rd or 4th day of the menstrual cycle (a day following the start of 
nafarelin nasal spray) FSH, follitropin-α (Gonal−F®; Merck-Serono, UK) or hMG 
(Menopur®; Ferring UK) was commenced at a dose of 450 IU daily by subcutaneous 
injection. A transvaginal ultrasound scan was performed nine days after starting ovarian 
stimulation and subsequent scans if necessary to assess follicular recruitment and growth. 
The woman was instructed to administer hCG injection subcutaneously when the criteria was 
met. FSH and nafarelin were continued until hCG administration. The trial intervention 
GnRH agonist short regimen is depicted in Figure 3.3. 
 
GnRH antagonist regimen 
With the GnRH antagonist regimen treatment was started on day 2 or 3 of the menstrual cycle 
after a transvaginal ultrasound scan confirming quiescent ovaries and a thin endometrium (≤ 
5mm endometrial thickness). The total AFC was measured in both ovaries at the time of this 
scan. Following the ultrasound scan ovarian stimulation was commenced with FSH, 
follitropin- α (Gonal−F®; Merck-Serono, UK) or hMG (Menopur®; Ferring UK) at a daily 
dose of 450 IU subcutaneously. A transvaginal ultrasound scan was performed on day 6 of 
ovarian stimulation to identify the leading follicle and scans were continued until the leading 
follicle had a diameter of ≥14mm which was usually between days 6 to 8 of stimulation. 
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 When the leading follicle had reached a diameter of 14mm, GnRH antagonist, cetrorelix 
(Cetrotide®; Merck-Serono, UK) 0.25mg daily was administered subcutaneously. A 
transvaginal ultrasound scan was performed on day 9 of ovarian stimulation and subsequent 
scans if necessary to assess follicular recruitment and growth. The woman was instructed to 
administer hCG injection subcutaneously when criteria for triggering ovulation was met. FSH 
and cetrorelix were continued until hCG administration. The trial intervention GnRH agonist 
















Day 1 of menstrual cycle 
GnRH agonist (nafarelin) commenced 
Period 
Day 1 of stimulation 
GnRH agonist (nafarelin) continued 
Ultrasound scan to 
assess follicular 
growth on day 9/10 
of stimulation 
hCG trigger, 34-38 hours 
prior to egg collection 
GnRH agonist (nafarelin) stopped 
Egg collection 
Embryo transfer 
Pregnancy test  
Progesterone luteal support Mid luteal phase of the menstrual cycle 
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Day 1 of menstrual cycle 
GnRH agonist (nafarelin) 
commenced; day 2/3 of cycle 
Day 1 of stimulation; 
day 3/4 of cycle 
GnRH agonist (nafarelin) continued 
GnRH agonist (nafarelin) stopped 
Egg collection 
Embryo transfer 
Pregnancy test  
Progesterone luteal support 
Period 
Ultrasound scan to 
assess follicular 
growth on day 9/10 
of stimulation 
hCG trigger, 34-38 hours 
prior to egg collection 
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Day 1 of menstrual cycle Day 1 of stimulation; 
day 2/3 of cycle 
hCG trigger, 34-38 hours 
prior to egg collection 
Pregnancy test  
Progesterone luteal support 
Period 
Scan on day 6 and further 
scans to identify lead follicle 
GnRH antagonist commenced 
when lead follicle is 14mm 
GnRH antagonist (cetrorelix) continued 
GnRH antagonist stopped 
Ultrasound scan to 
asses follicular 





 The following stages are the same for all the three treatment regimens. 
Criteria for hCG administration 
hCG, choriogonadotrophin-α injection (Ovitrelle®; Merck-Serono, UK) 6,500 IU was 
administered subcutaneously to induce ovulation when ≥ 3 follicles attained a mean diameter 
of ≥ 17mm. 
Oocyte retrieval (egg collection) 
Ultrasound guided oocyte retrieval was performed with the woman under deep sedation 
approximately 34-38 hours after the hCG injection. 
Embryo transfer 
Ultrasound guided embryo transfer was performed 2, 3 or 5 days following the oocyte 
retrieval, based on the number and quality of embryos available. 
Luteal support 
All women had progesterone for luteal support. Women were advised to self administer 
progesterone pessaries (Cyclogest®; Alpharma, UK) 400mg once or twice daily starting on 
the day of egg collection until the day of the pregnancy test, then until at least 8 weeks of 
pregnancy if the treatment was successful. 
Pregnancy test 
All women had a urinary pregnancy test around two weeks from the day of egg collection. 
Some women had a serum β hCG to test for pregnancy. 
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 Early pregnancy scans 
All women who had a successful IVF treatment outcome had two ultrasound scans in early 
pregnancy at around 6 – 7 weeks and 8 – 9 weeks gestation. 
 
3.5 Trial statistics 
3.5.1 Number of participants 
Sample size calculation was based on the observed differences in eggs collected from 
existing literature as well as on the judgement on what constituted as a clinically minimally 
important difference (MID), which was shown to be increasing the number of oocytes 
retrieved from 3 to 5. For this difference of two oocytes retrieved, with a standard deviation 
(SD) of 2.5 (as observed in the existing literature), for a power of 90% and an alpha of 5%, 
102 women in total needed to be recruited (34 each of the three arms of the trial). Previous 
studies have shown dropout rates to range between 4.5 – 4.8% (Cheung et al., 2005; Kucuk et 
al., 2008). However, assuming and adjusting for a worst case scenario of a 10% attrition a 
total of 37 participants needed to be recruited into each arm and the overall sample size for 
the study was 111 women. 
 
3.5.2 Statistical analysis 
The analysis was planned to be by ITT, and was intended to be carried out in the following 
four steps: 
Step 1: Summarising trial data 
Baseline data and outcome data were summarised separately. For continuous variables (eg 
age and FSH level), the distribution of the observations was examined, and if normally 
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 distributed they were summarised as means with SDs. If non-normally distributed, then 
medians and inter-quartile ranges (IQRs) were reported. Dichotomous data (eg clinical 
pregnancy), were reported as proportions (or percentages). For the main outcome measure 
(the number of oocytes collected), as the number of oocytes is not a dichotomous or 
continuous variable but is a count, and was likely not to be normally distributed, a model for 
count such as the negative binomial model was planned for analysis. 
 
In addition to the baseline and outcome data, other relevant data were also summarised such 
as the recruitment numbers, those participants lost to follow-up, protocol violations. 
 
Step 2: Inter-group comparisons 
A test for overall comparison (eg ANOVA, or if assumption for ANOVA was not met, a non-
parametric equivalence such as Kruskal-Wallis) was employed for each outcome across all 
three interventions (A, B, and C), and if this was found to be significant (at a p-value of 
≤0.05), pair-wise comparisons were planned (i.e., A vs B, B vs C, A vs C). As it was 
appreciated that the multitudes of pair-wise comparisons can suffer from Type I (false-
positive) error, adjustments were planned for multiplicity of comparisons (by using steps 
such as Bonferroni and Tukey’s procedure).  
 
The statistical procedures for pair-wise comparisons depended on the nature of the data: for 
example, for dichotomous outcomes, Fisher’s Exact or Chi2 test were used as appropriate, 
and for continuous outcomes the t-test was used if the observations in each trial arm were 
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 normally distributed; if non-normally distributed, then Mann-Whitney-U test was employed. 
P-values were reported to denote statistical significance. 
 
Step 3: Sub-group analysis 
Consideration was given for sub-groups analysis if possible. However, because sub-groups 
analysis can suffer from false positive (due to multiplicity of comparisons) and false negative 
(due to reduced sample sizes) results, limited importance was placed in subgroup findings in 
relation to the overall (global) findings. Post-hoc subgroup analysis was used only for the 
purpose of hypothesis generation. 
 
Step 4: Adjustments and sensitivity analyses 
If randomisation failed to achieve balanced groups, secondary analyses were planned with 
adjustment for unbalanced prognostic factors using procedures such as logistic regression. If 
the primary unadjusted analysis and secondary adjusted analysis were at discordance, it was 
decided to give greater weighting to the primary analysis in the interpretation of trial 
findings. 
 
For issues such as losses to follow-up, missing data, and protocol violations, it was planned to 
perform sensitivity analyses to explore the effect of these factors on the trial findings. As a 
secondary analysis, adjustments were planned for missing data using imputation techniques 




 3.5.3 Data and safety monitoring 
The trial was monitored by a data monitoring committee (DMC). The DMC was established 
to contain members who had no conflict of interest relating to the three trial protocols and 
had no involvement in running of any part of the trial. The DMC was responsible for data and 
safety monitoring. 
 
3.6 Approvals from regulatory authorities 
PRINT was set up and conducted according to the principles of Good Clinical Practice (GCP) 
as defined in the Medicines for Human Use (Clinical Trials) Amended Regulations 2006, the 
Research Governance Framework for Health & Social Care 2005 and the Data Protection 
Act. 
 
The research question was raised following the systematic review and meta-analysis on COH 
regimens for poor responders undergoing IVF treatment. The study protocol was developed 
by SKS and followed by internal and external expert peer review. The trial was initially 
started at the ACU, Guy’s and St Thomas’ NHS Foundation Trust and later extended to Lister 
Fertility Clinic, London following a substantial amendment to the trial protocol. The trial was 
funded internally by the ACU, Guy’s and St Thomas’ NHS Foundation Trust, London and 
the Lister Fertility Clinic, London at the respective sites. Guy’s and St Thomas’ NHS 
Foundation Trust was the sponsor for the trial with legal responsibilities in relation to the 
trial. The trial was registered on the EudraCT database and EudraCT number 2006 – 004460 - 
31 was obtained. The trial was also registered with the International Standard Randomised 
Controlled Trial Number (ISRCTN) register with a registration number: ISRCTN27044628. 
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 Applications were made to the Research Ethics Committee (REC) through an online NHS 
REC application form, and to the Research and Development (R&D) department for Guy’s 
and St Thomas’ NHS Foundation Trust (Appendices 4 & 5). Applications for REC and R&D 
authorisation were completed and co-ordinated by SKS. Application was also made to the 
Medicines for Human use Regulatory Authority (MHRA) for authorisation of a clinical trial 
of investigational medicinal product (CTIMP) as PRINT is a phase 4 CTIMP. Favourable 
ethical opinion was obtained from St Mary’s Hospital REC, London. SKS attended the REC 
meeting at which PRINT was considered for an ethical opinion (REC reference 
06/Q0403/157) (Appendix 6). Following approvals and permissions being granted by the 
R&D department (R&D reference RJI 07/0044) (Appendix 7) and the MHRA (MHRA 
reference 22282/0009/001-0004) (Appendix 8), recruitment into the trial was commenced at 
study site one; the ACU, Guy’s and St Thomas’ NHS Foundation Trust, London in March 
2007. 
 
The study was later extended to its second site, the Lister Fertility Clinic in 2009 by making 
substantial amendment to the protocol and obtaining approval from St Mary’s REC, the 
MHRA and the local R&D department for the Lister Fertility Clinic. All the essential 
documents for the conduct of the trial were maintained in the Trial Master File (TMF) at both 
sites and were secured safely. The trial intervention drugs (nafarelin and cetrorelix) were 
dispensed to participating women by an allocated clinical trials pharmacist at the respective 
sites. The investigators, doctors and pharmacists involved in the study had initial 





At every step during the conception and set up of the trial existing evidence was followed to 
justify the protocol. Where there was no substantial evidence a consensus of the clinicians 
from the two participating centres was obtained. A commonly recurring problem with 
previous studies on poor ovarian response was the lack of an evidence based definition of a 
poor responder. For the purpose of PRINT, a poor responder was defined as a woman who 
had a previous IVF treatment cycle in which she was stimulated with a daily dose of FSH of 
at least 300 I.U and produced either ≤ 3 mature follicles leading to cycle cancellation or had ≤ 
3 oocytes retrieved. Using a cut off of ≤ 3 oocytes retrieved was based on previous data that 
in women requiring a high gonadotrophin dose (total gonadotrophin dose > 3000 IU) for 
ovarian stimulation retrieval of < 4 oocytes is associated with a significantly lower clinical 
pregnancy rate compared to ≥ 5 oocytes (7% versus 25%; p < 0.05) (Kailasam et al., 2004). 
 
The trial inclusion criteria was set to include only women who had a stimulation dose of at 
least 300 IU FSH/ day and had a poor response in the previous cycle. This was based on 
previous research which showed that a low oocyte number was only detrimental if the 
cumulative dose of FSH used was > 3000 IU (Kailasam et al., 2004). The same study also 
demonstrated that cycle cancellation following ovarian stimulation with ≥ 300 IU FSH/ day 
was associated with significantly worse prognosis in a subsequent IVF cycle compared to 
cycle cancellation with a lower FSH dose. Hence definition of poor ovarian response should 
include the degree of ovarian stimulation used  
 
The age cut off over 40 years was based on the evidence that women older than 40 years of 
age differ in the poor response rate and embryo quality compared to younger women (Van 
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 Rooij et al., 2003). It was aimed to keep the study sample homogenous so that the evidence 
generated could translate to real clinical scenarios. The MID of an increase in the number of 
oocytes from 3 to 5 for sample size calculation was based on the evidence of a significantly 
lower clinical pregnancy rate with ≤ 3 oocytes retrieved (7%) compared to ≥ 5 oocytes 
retrieved (25%) (Kailasam et al., 2004). 
 
A dose of 450 IU of FSH daily was used for ovarian stimulation with the trial interventions. 
There is currently insufficient evidence from good randomised studies whether a 
gonadotrophin dose of > 300 IU/ day is beneficial for poor responders. A dose of 450 IU/ day 
was based on the consensus of clinicians from the two participating sites. Also it is the 
standard procedure at both the ACU and Lister Fertility Clinic of using 450 IU/ day of FSH 
for poor responders. This is in concordance with a recent world wide survey on the 
management of poor responders in which the majority of clinicians (51.6%) stated that they 
used a starting dose of between 375 IU – 600 IU of FSH daily (IVF-Worldwide, 2010). The 
majority of clinicians in this survey stated they would use a maximum stimulation dose of 
450 IU of FSH daily. 
 
The primary outcome for the trial was set as the number of oocytes retrieved reflecting the 
definition of poor ovarian response. The ideal outcome with IVF treatment is undoubtedly the 
occurrence of a live birth. A likely criticism with PRINT would be for not using live birth as 
the primary outcome. However, any study powered to detect differences in live birth rate for 
poor responders who have a poor prognosis and therefore low overall live birth rate is likely 
to involve a large sample size making such a study impractical. We therefore studied the 
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 relationship between the number of oocytes retrieved and live birth following IVF to justify 







Chapter 4  
Association between egg numbers and live birth in 








 4.1 Background 
The primary aim of IVF treatment for both clinicians and couples alike is to achieve a term 
live birth. The number of eggs retrieved is considered to be an important prognostic variable 
and therefore IVF treatment regimens aim to optimise this outcome. Studies evaluating IVF 
treatment regimens such as those relating to poor responders and studies of ovarian reserve 
tests such as anti-müllerian hormone (AMH) or AFC often use egg number as a surrogate 
outcome. However, this practice has been criticised (Vail and Gardner, 2003) as the 
relationship between egg number and live birth is poorly understood.  
 
Previous work on the relationship between the number of eggs retrieved and pregnancy rates 
following IVF treatment was based on data from single centres and involved small sample 
sizes (Meniru and Craft 1997; Letterie et al 2005;. Van der Gaast et al., 2006; Kably Ambe et 
al., 2008; Molina Hita Ma. del M et al., 2008; Hamoda et al 2010). These studies showed 
conflicting results and none of these studies reported live birth rates but instead reported on 
clinical or ongoing pregnancy rates. The aim of this work was to determine the association 
between the number of eggs retrieved and live birth rate in fresh IVF cycles and to identify an 
egg number that would optimise IVF outcome. A nomogram to predict live birth rate 
following IVF, based on the number of eggs retrieved and female age was established. 
 
4.2 Materials and methods 
Anonymised data were obtained from the Human Fertilisation and Embryology Authority 
(HFEA) for all IVF cycles performed in the UK from April 1991 to June 2008 
(www.hfea.gov.uk/5874.html). The HFEA, which is the statutory regulator of assisted 
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 conception treatment in the UK, has collected data on all IVF treatment cycles performed in 
the UK since its inception in 1991. Overall, 787,030 IVF cycles were recorded in this period. 
For the purpose of the study, cycles involving gamete or zygote intrafallopian transfer (GIFT, 
ZIFT), egg donation, egg sharing, embryo donation or where the source of embryos was not 
specified, pre-implantation genetic diagnosis (PGD), surrogacy, oocyte cryopreservation, 
frozen embryo replacement and cycles where no eggs were retrieved or all embryos were 
frozen were excluded from the analysis. Information was obtained on the number of eggs 
retrieved, age group of the women (18 – 34, 35 – 37, 38 – 39, 40 years and over), treatment 
period (1991 to 2008) and live birth outcome. A live birth is defined as any birth event in 
which at least one baby is born alive. 
 
4.2.1 Statistical analysis 
The characteristics of the cohort were described using absolute and relative frequencies for 
categorical variables, and means and medians with measures of spread for continuous 
variables. Crude live birth rates were computed for the whole cohort eligible for analysis, and 
stratified by period of treatment and age group of the women.  
 
To explore the association between egg number and live birth outcome, a maximum 
likelihood logistic model was fitted with live birth outcome as the dependent variable and 
using a fractional polynomial to handle egg number as a continuous independent variable. 
The closed test procedure for function selection as described by Royston and Sauerbrei was 
used (Royston and Sauerbrei, 2008). Indicator variables were introduced in the model, for age 
and period of treatment. Robust standard errors were computed to account for the non-
independence of observations from multiple treatment cycles in a single participant. The 
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 model calibration and discrimination ability was assessed by Hosmer-Lemeshow test and c-
index statistic.  
 
As the live birth outcome had substantially improved over the four time periods, the dataset 
generated after 2006 was used for the development of the prediction model. As the age of the 
woman has an important impact in determining the probability of a live birth, this probability 
was computed stratified by age group. In order to validate the model the cohort was split into 
two parts according to the period of treatment. The first, comprising cycles performed 
between 2006 and 2007, was used to derive the model while data generated from 2008 
onwards were used to validate it. Finally, a nomogram was constructed to calculate the 
probability of a live birth based on egg number and age.  
 
4.3 Results 
Of the 787,030 cycles recorded, 400,135 cycles were eligible for analysis. One hundred and 
forty six cycles involving GIFT, ZIFT, 24,684 cycles involving egg donation or egg sharing, 
3,335 cycles involving embryo donation, 200,985 cycles where the source of embryos was 
not specified, 1,222 PGD cycles, 891 cycles involving surrogacy, 575 cycles involving 
oocyte cryopreservation, 98,257 frozen embryo replacement cycles, 35,121 cycles where no 
eggs were retrieved and 10,183 cycles with no embryo transfer in the fresh cycle, 9,377 
cycles with missing data and 2,119 cycles that were performed for reasons other than 
treatment were excluded from the analysis (Figure 4.1).  
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 Figure 4.1: Data selection process to examine the association between egg numbers and live 

















Total number of cycles recorded in the HFEA database from 1991 to 2008: n = 787,030 
Cycles excluded with reasons 
• No data or unclear data for either 
baseline or outcome variables:             
n = 9,377 
• Frozen cycles: n = 98,257 
• Donated embryos: n = 3,335 
• Source of embryos not specified:           
n = 200,985 
• Surrogacy: n = 891 
• PGD cycles: n = 1,222 
• Egg donor or egg share donor 
cycles: n = 24,684 
• Cycles involving thawed eggs:          
n = 38 
• Cycles involving egg storage:          
n = 537 
• Cycles with no eggs retrieved:             
n = 35,121 
• Reasons for producing embryos 
other than treatment: n = 2,119 
• IVF + GIFT or ZIFT: n = 146 
• Cycles with no fresh embryo 
transfer where all embryos were 
stored: n = 10,183 
Total number of fresh IVF or ICSI cycles analysed: n = 400,135 
Data for model derivation (2006 – 
2007): n = 63,635 
Data for model validation (2008):.......  
n = 17,366 
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 Table 4.1: Characteristics of the cohort of 400,135 IVF cycles 
Characteristic  n (%) 
Age (given categories) 
  18 – 34 years 
  35 – 37 years 
  38 – 39 years 
  40 years and over 
 
200, 982 (50·2) 
97, 345 (24·3) 
51, 385 (12·8) 
50, 423 (12·6) 
Number of previous IVF cycles  
  0 
  1 
  2 
  3 or more 
 
230, 924 (58·8) 
87, 471 (22·3) 
40, 994 (10·4) 
33, 157 (8·5) 
Previous LB (yes) 18, 633 (4·7) 
Cause of infertility† 
  Male Factor 
  Tubal disease 
  Ovulatory disorder 
  Endometriosis 
  Unexplained  
 
221, 047 (56·3) 
117, 722 (30·3) 
46, 071 (11·9) 
29, 804 (7·5) 
131, 652 (33·7) 
Treatment type 
  IVF 
  ICSI   
 Unknown 
 
247, 640 (61·9) 
151, 788 (37·9) 
707 (0·2) 
Eggs retrieved (Figure 2a) 
Median (IQR) 
 
9 (6 – 13) 
Embryos created (Figure 2b) 
Median (IQR) 
 
5 (3 – 8) 
Treatment cycles in each period  
  1991 – 1995 
  1996 – 2000 
  2001 – 2005 
  2006 onwards 
 
72, 682 (18·2) 
117, 050 (29·3) 
129, 402 (32·3) 
81, 001 (20·2) 
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 Half (50.2%) of all the cycles were conducted on women aged 34 years or below whilst 
12·6% were in women aged 40 years or over. Majority (58.8%) of women were having their 
first IVF cycle while 22.3% had one previous, 10.4% had two previous and 8.5% had three or 
more previous cycles. The major cause of infertility was male factor (56·3%) and 
conventional IVF was used in the majority (61·9%) of cycles. The characteristics of the 
analysis cohort are given in Table 4.1. 
 
The median number of eggs retrieved was 9 (IQR 6 – 13) (Figure 4 2a) and the median 
number of embryos was 5 (IQR and 3 – 8) (Figure 4 2b). The overall live birth rate in the 
entire cohort of 400,135 cycles was 21·3% (95% CI 21·2 – 21·4%), with a gradual rise over 
the four stratified time periods. The live birth rate was 14·9% in 1991 – 1995, 19·8% in 1996 
– 2000, 23·2% in 2001 – 2005, and 25·6% in 2006 – 2008). 
 




 Association between egg number and live birth 
There was a strong association between egg number and live birth rate. The live birth rate 
rose with increasing number of eggs retrieved up to about 15, plateaued between 15 to 20 
eggs and steadily declined beyond 20 eggs (Figure 4.3a). There was an initial linear 
relationship between the number of eggs and live birth rate but an overall non linear 
relationship between the egg number and live birth rate following IVF. The same pattern of 
association between egg number and live birth rate was observed in all four time periods 
(1991 – 1995, 1996 – 2000, 2001 – 2005, and 2006 – 2008). For a given number of eggs live 
birth rates increased over time (Figure 4.3b) but decreased with increasing age (Figure 4.3c). 
The increase in live birth rates over time for a given number of eggs is a likely reflection of 
improvements in laboratory techniques and clinical practices in IVF. 
 




 Figure 4.3b: Association between egg number and live birth rate stratified by time period 
 




 Predicting live birth 
To ensure that the predicted live birth rate was relevant to current practice, the predictive 
model was derived from observations generated from data on treatments from 2006 to 2007. 
The data from 2008 were used for model validation. The final model, which included non-
linear terms for egg number and age as indicator variable, closely fitted with observed data 
(Figure 4.4). The model was well calibrated, the Hosmer Lemeshow Chi2 was 3·92 [degrees 
of freedom (df) = 8, p = 0·86] and the c-index was 0·65.  
 





 The predicted probability of live birth for a given egg number and age group is graphically 
depicted in the nomogram (Figure 4.5) and summarised in Table 4.2. 
 




To demonstrate an example of using the information above, for a woman aged 34 years or 
below the predicted live birth is 7% with one egg and 33% with seven eggs retrieved 
whereas, for a woman aged 40 years or over the predicted live birth with one egg is 2% and 
seven eggs is 12%.
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 Table 4.2. Predicted probabilities for live birth for egg number and age 






































1 253 8 7 7, 8 275 7 6 6, 7 280 5 4 4, 5 541 1 2 2, 3 
2 540 17 16 15, 17 579 14 14 13, 14 509 9 9 9, 10 774 5 5 5, 5 
3 819 21 22 21, 22 840 18 19 18, 19 718 12 13 13, 14 1002 6 7 7, 8 
4 1221 29 26 25, 26 1091 22 22 22, 23 817 17 16 15, 17 1025 9 9 8, 9 
5 1486 29 29 28, 29 1245 24 25 24, 26 899 18 18 17, 19 1058 11 10 10, 11 
6 1684 30 31 30, 31 1298 27 27 26, 28 854 18 20 19, 21 980 9 11 11, 12 
7 1809 35 33 32, 33 1321 29 29 28, 30 846 21 21 20, 22 901 11 12 11, 13 
8 1904 34 34 34, 35 1278 29 30 30, 31 729 23 22 22, 23 771 11 13 12, 14 
9 1898 35 36 35, 36 1207 31 31 31, 32 672 23 23 23, 24 627 15 14 13, 14 
10 1805 36 37 36, 37 1168 31 33 32, 33 630 25 24 23, 25 538 14 14 13, 15 
11 1795 36 38 37, 38 1035 34 33 33, 34 549 23 25 24, 26 466 17 15 14, 15 
12 1639 38 38 38, 39 872 34 34 33, 35 474 26 26 25, 27 401 15 15 14, 16 
13 1484 38 39 38, 40 703 34 35 34, 36 411 26 26 25, 27 298 16 15 15, 16 
14 1291 40 40 39, 40 675 37 35 34, 36 329 26 27 26, 28 252 16 16 15, 17 
15 1155 40 40 39, 41 526 41 36 35, 37 256 26 27 26, 28 229 17 16 15, 17 
20 487 41 41 41, 42 219 36 37 36, 38 93 29 28 27, 29 74 18 17 16, 18 
25 172 42 41 40, 43 63 43 37 36, 38 37 30 28 27, 30 19 26 17 16, 18 
30 67 31 40 38, 42 20 50 36 33, 38 4 0 27 25, 29 12 25 16 14, 18 
35 14 29 37 33, 41 7 29 33 29, 37 5 0 25 22, 28 0 - 15 13, 17 
40 15 27 33 28, 40 7 43 30 24, 35 2 50 22 18, 27 0 - 13 11, 16 
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 Validation of the prediction model was performed on 17,366 IVF cycles and 4,863 live births 
from 2008 data. The predictive ability of the model did not differ between the derivation and 
validation cohorts. Although the Hosmer Lemeshow Chi2 16·3, (df = 8, p = 0·04) was 
statistically significant due to the large sample size, the differences between predicted and 
observed live birth probabilities are clinically unimportant (Figure 4.6). The c-index was 0·66 
for the temporal validation cohort. 
 






























Circles indicate the observed proportion of live births per tenth of predicted probability. 






 4.4 Discussion 
The results of the study show a strong relationship between the number of eggs retrieved and 
live birth rate in a fresh IVF cycle. The largest available clinical IVF database was used to 
assess the association between egg number and live birth in a fresh IVF cycle. Although the 
clinical heterogeneity within the dataset was considered a drawback, such differences 
increase the generalisability of the findings. Only cycles with ovarian stimulation were 
included in the analysis. This excluded natural cycles as it was our intention that the number 
of oocytes should reflect the ovarian reserve. Although it was appreciated that there would 
have been a variation in the gonadotrophin stimulation dose, the vast majority of the cycles 
would have had adequate stimulation given in accord with the overall practice in the UK. 
Therefore the ovarian response to stimulation quantified as the number of oocytes retrieved 
was likely to be a reasonable reflection of the ovarian reserve potential. The prediction model 
was derived using more recent data (2006–2007) which closely represent current practice and 
validated using the most recent subset of IVF cycles within the cohort (2008) constituting a 
temporal external validation. 
 
Previous studies looking at the relationship between the number of eggs and pregnancy rates 
have reported inconsistent results in showing that pregnancy rates increased with increasing 
number of eggs (Meniru and Craft, 1997), best pregnancy rates being obtained with egg 
numbers of 10–15 (van der Gaast 2006; Kably Ambe A et al., 2008), or 7–16 eggs (Molina 
Hita Ma. del M et al., 2008). Furthermore, these studies involved small numbers and were 
reported from single centres which limited their generalisability. This study is the first to 
provide vital information on predicting live birth rate on the basis of eggs retrieved in women 
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 of different age groups. The simplicity of the nomogram facilitates interpretation of this 
information by clinicians as well as couples seeking IVF treatment. 
 
Knowledge of factors predicting IVF success is critical to patients and clinicians in informing 
decisions to embark on IVF treatment and choice of ovarian stimulation regimens. Such 
information is also helpful in counselling couples about deciding against further IVF 
treatment or plans to opt for donor eggs. To date, most clinical decisions on ovarian 
stimulation in IVF have been based on ovarian reserve tests which are good at predicting 
numbers of eggs retrieved but poor in terms of predicting live birth (Broekmans et al., 2006; 
Broer at al., 2009). By allowing clinicians to link the (predicted) egg number from ovarian 
reserve tests to live birth, the nomogram generated by this study is likely to facilitate use of 
these tests to optimise outcomes in IVF whilst preventing complications such as OHSS 
relating to production of excessive number of eggs.  
 
There has been a recent trend towards mild ovarian stimulation in IVF with the emphasis on 
recovering fewer eggs than previously deemed as optimal (Fauser et al., 2010). The findings 
of this study support the use of moderate stimulation protocols over mild or aggressive 
stimulation protocols in IVF treatment. The nomogram that has been established is the first of 
its kind that allows prediction of live birth for a given egg number and female age group. This 
is potentially valuable for patients and clinicians in planning IVF treatment protocols and 
counselling regarding the prognosis for a live birth occurrence, especially in women with 




 The relationship observed between the number of eggs retrieved and live birth in a fresh IVF 
cycle and the initial linear relationship between egg number and live birth justified using the 
















 5.1 Background 
The number of oocytes retrieved following COH has been demonstrated to be an important 
prognostic variable in IVF treatment as there is a strong association between the number of 
oocytes retrieved and live birth following IVF (demonstrated in Chapter 4). Women with 
poor ovarian response have a suboptimal outcome as the number of oocytes retrieved and 
embryos available for transfer influence the prognosis for the success of IVF treatment (Ulug 
et al., 2003). The management options for women with a poor response to COH are either 
cycle cancellation and expectation for managing the cycle better or differently next time, or 
continuing the IVF treatment cycle and hoping for an acceptable outcome despite the low 
oocyte numbers. The rationale for suggesting treatment in a different cycle is based on the 
idea that a different cohort of pre antral and antral follicles in each cycle might result in a 
different outcome. When faced with either expected or unexpected poor ovarian response, the 
decision of whether to cancel the cycle with the intention to start again or go ahead with 
oocyte retrieval is a difficult one involving emotional, financial and logistic implications with 
scant published data to justify either option. This is not an uncommon situation for IVF 
clinicians encountering an increasing burden of poor ovarian response (IVF-Worldwide, 
2010) as a consequence of women delaying childbirth (Bewley et al., 2005) and older women 
seeking IVF treatment (http://www.hfea.gov.uk/ivf-figures). 
 
Previous studies on intercycle variability of ovarian reserve tests reported a high cycle to 
cycle variability in women with low ovarian reserve and a poor response to ovarian 
stimulation (Scott et al., 1990, Kwee et al., 2004). Knowledge of intercycle variability in poor 
responders is important for the counselling of these women in their choice of management. 
Whether there is any cycle to cycle variation in their response to COH remains unknown and 
has never been tested previously. In order to try and address this question, I analysed two 
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 consecutive IVF cycles which had identical COH regimens using the same daily dosage of 
gonadotrophin in women who were identified as poor responders. 
 
5.2 Materials and methods 
5.2.1 Study population 
Women undergoing two consecutive IVF ± ICSI treatment cycles within a one year interval 
over a three and a half year period (February 2008 to August 2011) and stimulated with 450 
IU of gonadotrophin daily and the same COH regimen in both the cycles were evaluated. It is 
the policy at the ACU to use the maximum daily dose of 450 IU of gonadotrophin only for 
those women identified to have either a diminished ovarian reserve or poor ovarian response 
in a previous cycle, diminished ovarian reserve being defined by an elevated early follicular 
phase serum FSH value of ≥ 10 IU/ l and or an AFC of ≤ 10. It is also Unit policy to use a 
stimulation dose of either 300 IU or 450 IU of gonadotrophin/day at the discretion of a 
clinician in women with diminished ovarian reserve and a dose of 450 IU of gonadotrophin 
per day for women with a previous poor ovarian response.  
 
Data from all patients having treatment at the ACU are recorded prospectively in an 
electronic database (ACU base, London, United Kingdom). The database was searched to 
identify all women who had two consecutive IVF ± ICSI treatment cycles with the same 
COH regimen and stimulation dose of 450 IU of gonadotrophin daily between February 2008 




 5.2.2 Treatment protocol 
The COH regimens used for each woman in both the IVF cycles were the GnRH agonist long 
regimen, the GnRH agonist short regimen or the GnRH antagonist regimen. Details of these 
regimens are as described previously in Chapter 3. Briefly, with the GnRH agonist long 
regimen pituitary down regulation with nafarelin nasal spray 400 micrograms twice daily 
(Synarel®; Pharmacia, UK) is commenced in the mid-luteal phase of the menstrual cycle and 
continued for two weeks. This is followed by an ultrasound confirmation of down regulation 
when the AFC is recorded and ovarian stimulation with gonadotrophin (FSH) injections 
(Gonal−F®; Merck-Serono, UK, Menopur®; Ferring, UK) at a dose of 450 IU/ day is 
commenced and continued with a reduced dose of nafarelin 200 micrograms twice daily until 
the administration of hCG injection. The hCG injection (Ovitrelle® 6,500 IU/ day; Merck-
Serono, UK) was administered when the follicles reached the preovulatory stage (≥ 17 mm 
diameter), aiming for at least 3 follicles ≥ 17 mm. With the GnRH agonist short regimen 
nafarelin nasal spray is commenced on day 2 or day 3 of the cycle following an ultrasound 
scan confirming quiescence of the ovaries and determination of AFC. Nafarelin is 
administered at a dose of 200 micrograms twice daily followed by FSH injections at a dose of 
450 IU/ day commenced a day later. Both nafarelin and FSH injections are continued until 
the administration of hCG. With the GnRH antagonist regimen FSH injections are 
commenced on day 2 or day 3 of the cycle at a dose of 450 IU/ day following an ultrasound 
scan. The GnRH antagonist cetrorelix (Cetrotide®; Merck-Serono, UK) is administered at a 
dose of 0.25 mg daily when the lead follicle reaches a diameter of ≥14mm. Both the FSH and 




 Transvaginal ultrasound guided oocyte retrieval (TVOR) was performed 34 – 38 hours 
following the hCG injection. Embryo transfer was performed with transabdominal ultrasound 
guidance 2, 3 or 5 days following oocyte retrieval depending on the number and quality of 
the embryos. The number of embryos replaced into the uterine cavity was guided by our Unit 
policy and was determined by the age of the woman, quality of the embryos and previous 
history. 
 
All women were given luteal phase support with progesterone pessaries 400 mg once or twice 
daily (Cyclogest®, Alpharma, UK) commencing on the day of oocyte retrieval and continued 
until the pregnancy test or until 8 weeks gestation if pregnant. A urine pregnancy test and or a 
serum β hCG was performed approximately 2 weeks after TVOR. 
 
5.2.3 Outcome variables and statistical analysis 
The outcome measures analysed were the number of oocytes retrieved, the number of 2 
pronucleate (2PN) embryos, the fertilisation rate, the number of embryos transferred, 
pregnancy rate and clinical pregnancy rate. Data was summarised using means and SDs or 
median and IQR (depending on the distribution) for quantitative variables and percentages for 
categorical variables. The paired t-test was used for comparison of continuous variables such 
as maternal age, AFC, number of oocytes retrieved (normal distribution in this group of 
women) and number of embryos transferred. The Chi2 test and Fisher’s exact test were used 
to compare fertilisation and pregnancy rates. A pregnancy outcome refers to a biochemical 
pregnancy diagnosed by a positive urine pregnancy test or serum β hCG and a clinical 
pregnancy was defined as the detection of a fetal heart beat on ultrasound scan.  All statistical 
analyses were performed using SPSS statistics 17. 
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 5.3 Results 
During the three and a half year period from February 2008 to August 2011 there were 74 
women who had two consecutive cycles of IVF ± ICSI treatment with stimulation dose of 
450 IU of FSH daily. Forty five among the 74 women had the same COH regimen in the two 
successive IVF cycles within a period of one year. The remaining 29 women either had 
different COH regimens in the subsequent cycle or had the two cycles more than 12 months 
apart and were excluded from the analysis. As the aim of the study was to establish if there 
was any physiological variation in response to stimulation, women were analysed only if they 
had identical regimens in the two cycles. IVF cycles more than one year apart were excluded 
to prevent the influence of the declining ovarian reserve with time.  
 
Two women were excluded from the analysis as there were undergoing PGD which would 
alter the embryo numbers available for transfer, and a further two women were excluded as 
they had a cycle which was cancelled before oocyte retrieval. As we intended to provide 
objective data we excluded women whose cycles were cancelled before oocyte retrieval. At 
the ACU, women with ≤ 3 mature follicles following COH are given the option of either 
cancelling their cycle or proceeding with IVF treatment. Thus 41 women undergoing 82 IVF 
cycles were eligible for the final analysis. Each woman therefore acted as her own control 
and there was obviously no live birth following the first IVF cycle. The data selection process 


























Total number of women who had two consecutive IVF cycles with a daily dose of 450 IU of 
FSH/ day in the period August 2009 to July 2011: n = 74 
Number of women who had two successive IVF cycles with a daily dose of 450 IU of 
FSH/ day and the same COS regimen within 12 months: n = 45 
Women with the successive cycles more 
than 12 months apart or different COS 
regimens: n = 29 
Cycles excluded with reasons 
• PGD cycles: n = 2 
• Cancelled cycles: n = 2 
Number of women eligible for analysis: n = 41 





 The mean age of women in their first cycle evaluated was 39 ± 3.28 years, the mean age in 
the subsequent cycle was 39.83 ± 3.03 years and women were significantly older in their 
second cycle compared to their previous cycle (p < 0.001). Fourteen women had the GnRH 
agonist long regimen, 19 women had the GnRH agonist short regimen and eight women had 
the GnRH antagonist regimen in the two successive cycles. 
 
As the number of oocytes in this group of women had a normal distribution, data was 
summarised using mean and SD. There was no statistically significant difference in the mean 
number of oocytes retrieved in the first cycle evaluated and the subsequent cycle (5.39 ± 
3.470 and 5.39 ± 3.405; p = 1.00). There was no statistically significant difference in the 
mean number of 2PN embryos formed (2.34 ± 1.71 vs. 2.44 ± 1.99, p = 0.80) and the mean 
number of embryos transferred (1.63 ± 0.80 vs. 1.49 ± 1.00, p = 0.44) in each cycle. There 
were no significant differences in the fertilisation rate (61% vs. 66.2%, p = 0.56), pregnancy 
rate (19.5% vs 26.8%, p = 0.18) nor in clinical pregnancy rate (9.76% vs. 19.5%, p = 0.17) 
between the two successive cycles (results summarised in Table 5 1). 
 
A subgroup analysis was performed for women aged less than 37 years to determine if age 
has an impact on intercycle variability. In women aged less than 37 years there were no 
significant differences in the mean number of oocytes retrieved (4.91 ± 1.92 vs. 6.09 ± 3.08, 
p = 0.36), mean number of 2 PN embryos (1.91 ± 1.3 vs. 3.00 ± 0.52, p = 0.11), mean 
number of embryos transferred (1.36 ± 0.80 vs. 1.64 ± 0.51, p = 0.28), fertilisation rate 
(55.5% vs. 45.9%, p = 0.20), pregnancy rate (36.4% vs. 45.5%, p = 0.24) and clinical 
pregnancy rate (18.2% vs. 36.4%, p = 0.11) in the two successive cycles (results summarised 
in Table 5 2). 
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 Table 5.1: Treatment outcome in the two successive IVF cycles 
 
 First IVF cycle Second IVF cycle p value 
Number of cycles 
(N) 
41 41  
Age in years (mean 
+/- SD) 
39.39 +/- 3.28 39.83 +/- 3.03 p < 0.001 
Number of oocytes 
(mean +/- SD) 
5.39 +/- 3.470 5.39 +/- 3.405 p = 1.00 
Number of 2PN’s 
(mean +/- SD) 
2.34 +/- 1.71 2.44 +/- 1.99 p = 0.80 
Fertilisation rate 61% 66.2% p = 0.56 
Number of embryos 
transferred (mean 
+/- SD) 
1.63 +/- 0.80 1.49 +/- 1.00 p = 0.44 
Pregnancy (%) 8/41 (19.5%) 11/41 (26.8%) p = 0.18 
Clinical pregnancy 
(%)  
4/41 (9.76%) 8/41 (19.5%) P = 0.17 
 
 
Table 5 2: Treatment outcome in the two successive IVF cycles in women aged < 37 years 
 First IVF cycle Second IVF cycle p value 
Number of cycles (N) 11 11  
Age in years (mean 
+/- SD) 
35.00 +/- 1.18 35.82 +/- 1.25 p < 0.001 
Number of oocytes 
(mean +/- SD) 
4.91 +/- 1.92 6.09 +/- 3.08 p = 0.36 
Number of 2PN’s 
(mean +/- SD) 
1.91 +/- 1.3 3.00 +/- 0.52 p = 0.11 
Fertilisation rate 55.5% 45.9% p = 0.20 
Number of embryos 
transferred (mean +/- 
SD) 
1.36 +/- 0.80 1.64 +/- 0.51 p = 0.28 
Pregnancy (%) 4/11 (36.4%) 5/11 (45.5%) P = 0.24 
Clinical pregnancy 
(%) 




 5.4 Discussion 
This study was carried to reflect a commonly encountered scenario in real clinical settings. 
The question of whether to continue with the IVF cycle or cancel the cycle and re start 
treatment is a frequently encountered dilemma in both presumed and proven poor responders. 
Hence, it was decided to include women with diminished ovarian reserve in addition to 
previous poor responders in this study. The results of this study failed to show any 
physiological intercycle variability in poor responders undergoing IVF treatment. This is the 
first study to objectively evaluate the IVF outcomes in the same woman having identical 
treatment regimens in sequential cycles to determine whether there is any natural variation. 
This finding tends to undermine the assumption that, as there is a different cohort of follicles 
recruited in each cycle, there could be cycle to cycle variability in women. This study also 
provides answer to the dilemma as to whether postponing treatment and initiating a different 
cycle could result in a different/ better outcome in poor responders. Furthermore, although 
women were significantly older in their second compared to their first cycle (39.39 ± 3.28 vs. 
39.83 ± 3.03, p < 0.001), the IVF outcomes were not significantly different. This is 
potentially valuable information that could be conveyed to women in their decision regarding 
timelines for attempting a further IVF cycle. 
 
The weakness of this study is the relatively small number of women analysed. We identified 
only 41 women to be included in the study as there is a tendency for clinicians and for 
women with poor ovarian response to modify the regimen in subsequent cycles in the hope 
that a change in the regimen will produce a different outcome. However, there is currently 
insufficient evidence to suggest any particular regimen to be advantageous for poor 
responders undergoing COH and IVF treatment (as discussed in Chapter 2) which has led to 
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 the PRINT study. Previous studies which addressed intercycle variability of ovarian reserve 
tests found cycle to cycle variation in serum basal FSH, AFC and clomiphene citrate 
challenge tests (CCCT) in women with low ovarian reserve (Scott et al., 1990; Kwee et al., 
2004). However, a study by Abdalla and Thum (2004) reported no difference in IVF 
outcomes in women with diminished ovarian reserve or poor ovarian response irrespective of 
an elevated or normal serum basal FSH value prior to the treatment cycle. Another study 
comparing the management options of proceeding with egg collection versus cycle 
cancellation and starting another IVF cycle in women with poor response showed that cycle 
cancellation and a further attempt did not improve outcome (Nicopoullos and Abdalla 2011). 
 
The findings of this present study are useful in counselling patients undergoing IVF treatment 
about their options when faced with poor response to ovarian stimulation. Such women 
should be informed that they are likely to have a similar outcome in subsequent cycles. The 
option for such women would be to continue treatment and proceed with egg collection rather 
than cancelling the cycle with a view to having a subsequent attempt. This would be the most 

















 6.1 Background 
SKS oversaw the conduct of PRINT at both sites in collaboration with the joint clinical trials 
office (JCTO), Guy’s and St Thomas’ NHS Foundation Trust and King’s College London. 
Eligible and consenting women undergoing IVF treatment at the ACU, Guy’s and St 
Thomas’ NHS Foundation Trust and the Lister Fertility Clinic were recruited into PRINT. 
The study was conducted between March 2007 and May 2012. The study was closed at both 
sites following ‘declaration of end of trial’ to the REC and MHRA. Women were assessed for 
eligibility and as detailed in Chapter 3, PRINT was discussed with eligible women who had 
poor ovarian response to COH in a previous IVF cycle and were intending to undergo a 
subsequent IVF treatment cycle. Consenting women were randomised to one of the three trial 
interventions (the GnRH agonist long, the GnRH agonist short or the GnRH antagonist 
regimen) using internet randomisation which ensured allocation concealment. 
 
All participants had comprehensive evaluation involving full history taking. At the initial 
assessment special note was made of variables such as the age of the woman, BMI, serum 
follicular phase FSH and oestradiol levels, AFC and the duration, cause and type of 
subfertility. Details regarding the number of previous IVF cycles the women had undergone, 
number of previous IVF cycles with a poor ovarian response and the number of previous 
pregnancies and live births including those following IVF treatment were also recorded. All 
variables were entered into the trial CRF by SKS and checked for accuracy by the clinical 
research associate (CRA) during the trial monitoring visits. 
 
The study was monitored twice yearly or more frequently by a CRA from the JCTO, Guy’s 
and St Thomas’ NHS Foundation Trust and King’s College London to ensure adherence to 
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 the protocol. Annual reports regarding progress of the trial were submitted to the REC by 
SKS. Safety reports were submitted to the MHRA annually and no serious adverse events 
(SAEs) or suspected unexpected serious adverse reactions (SUSARs) were reported during 
the study period. All correspondence and documents pertaining to the study were maintained 
in the TMF at both sites. 
 
6.2 Enrolment and recruitment into PRINT 
Eligible women who were intending to have an imminent IVF treatment cycle and agreed to 
participate in the trial by signing the trial consent form were randomised to the trial 
interventions by SKS using internet randomisation at www.medscinet.com/print. The woman 
was informed of the IVF regimen she was randomised to and the details of the treatment were 
discussed and explained.  
 
A total of 113 women were enrolled into the study. Two women withdrew consent and 111 
women were randomised into the study with 37 women in each of the three arms. Of the 111 
women 92 women received the intervention to which they had been allocated. Details of the 
regimens and participant flow through the trial are as described in Chapter 3. Thirty one 
women underwent COH with the GnRH agonist long regimen (Group A), 31 women with the 
GnRH agonist short regimen (Group B) and 30 women with the GnRH antagonist regimen 
(Group C). Of the 19 women who did not receive the allocated intervention, three women 
conceived spontaneously while waiting to start the IVF treatment cycle and 16 women 
decided later not to pursue further IVF treatment. The consolidated standards of reporting 
trials (CONSORT) flow diagram for PRINT is presented in Figure 6.1.
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 Figure 6.1: CONSORT flow diagram for PRINT 
Analysed (n= 37) 
♦ Excluded from analysis (n= 0) 
Lost to follow-up (n= 0) 
Discontinued intervention (n=0) 
Allocated to GnRH agonist long regimen (n= 
37) 
♦ Received allocated intervention (n= 31) 
♦ Did not receive allocated intervention with 
reasons (n= 6) 
 Decided not have further IVF  
treatment (n= 5) 
 Spontaneous pregnancy (n= 1) 
  
Lost to follow-up (n= 0) 
Discontinued intervention (n= 0) 
Allocated to GnRH agonist short regimen (n= 
37) 
♦ Received allocated intervention (n= 31) 
♦ Did not receive allocated intervention with 
reasons (n= 6) 
 Decided not have further IVF  
treatment (n= 5) 





Randomised (n= 111) 
Allocated to GnRH antagonist regimen (n= 
37) 
♦ Received allocated intervention (n= 30) 
♦ Did not receive allocated intervention with 
reasons (n= 7) 
 Decided not have further IVF  
treatment (n= 6) 
 Spontaneous pregnancy (n= 1) 
 
Lost to follow-up (n= 0) 
Discontinued intervention (n= 0) 
Analysed (n= 37) 
♦ Excluded from analysis (n= 0) 
Analysed (n= 37) 
♦ Excluded from analysis (n= 0) 
Enrolled (n= 113) 




 6.3 Statistical analysis 
The analysis was by ITT. Baseline data and outcome data were summarized separately. For 
continuous variables the distribution of the observations was examined, and if normally 
distributed they were summarized as means with SDs. If non-normally distributed, medians 
IQRs were planned. Dichotomous data were reported as percentages. 
 
A test for overall comparison (eg ANOVA, or if assumption for ANOVA was not met, a non-
parametric equivalence such as Kruskal-Wallis) was employed for each outcome across all 
three interventions (A, B, and C), and if this was found to be significant (p-value of ≤ 0.05), 
pair-wise comparisons were planned (i.e., A vs. B, B vs. C, A vs. C). The statistical 
procedures for pair-wise comparisons depended on the nature of the data: for example, for 
dichotomous outcomes, Fisher’s Exact or Chi2 test were used as appropriate, and for 
continuous outcomes the t-test was used if the observations in each trial arm were normally 
distributed; if non-normally distributed, then Mann-Whitney-U test was planned. As the data 
for all continuous variables and the outcome of number of eggs retrieved was normally 
distributed results are given using parametric tests. The outcome of number of oocytes in 
poor responders had a normal distribution. All statistical analyses were performed using 
SPSS statistics 17. 
 
6.4 Results 
The demographic variables of women randomised into each of the three regimens are 
compared in Table 6.1. There were no significant differences between the three groups in the 
baseline characteristics such as age on day 1 of gonadotrophin stimulation, BMI, duration of 
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 infertility, type of infertility, previous IVF attempts with poor ovarian response, previous 
pregnancies including previous IVF pregnancies and previous live births. The three groups 
were also comparable with regards to the baseline serum FSH, baseline serum oestradiol 
levels and AFC.  
 
The overall mean age of women in the study was 37.0 ± 2.9 years, the mean basal serum FSH 
level was 10.6 ± 4.7 IU/ l, the mean basal serum oestradiol level was 177.6 ± 140.1 pmol/ l 
and the mean AFC was 6.6 ± 2.5. The major cause (47.7%) of infertility was unexplained 
(53/111), 31.5% (35/111) had a male factor cause, 16.2% (18/111) had a tubal factor and 
4.5% (5/111) had other factors such as endometriosis, fibroids as the sole cause of infertility. 
 
The stimulation characteristics of the three groups are shown in Table 6.2. There was a 
significant difference in the mean duration of stimulation between the three regimens (p = 
0.006). Pair-wise comparisons of GnRH agonist long versus GnRH agonist short and GnRH 
antagonist regimens showed that the duration of stimulation was significantly longer with the 
GnRH agonist long compared to the agonist short regimen (12.4 ± 2.7 days vs. 10.5 ± 2.4 
days, p = 0.005) and with the GnRH agonist long compared to the GnRH antagonist regimen 
(12.4 ± 2.7 days vs. 10.5 ± 2.5 days, p = 0.009), but there was no significant difference 
between the GnRH agonist short and the GnRH antagonist regimens (10.5 ± 2.4 days vs. 10.5 
± 2.5 days, p = 0.91). There was also a significant difference in the total gonadotrophin 
consumption between the three groups (p = 0.01). Pair-wise comparisons showed that the 
total gonadotrophin consumption was significantly higher with GnRH agonist long compared 
to the GnRH agonist short and the GnRH antagonist regimens (5540.32 ± 1216.1 IU vs. 
4819.35 ± 1145.5 IU, p = 0.02 and 5540.32 ± 1216.1 IU vs. 4740.0 ± 1131.9 IU, p = 0.01 
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 respectively). There was no significant difference in the total dose of gonadotrophin 
consumption between the GnRH agonist short and GnRH antagonist regimens (p = 0.81). 
 
There was no significant difference between the three regimens in the number of cycles 
cancelled before oocyte retrieval (where no follicles were recruited despite maximal 
gonadotrophin stimulation of 450 IU/ day for > 8 days). There was a significant difference in 
the mean number of oocytes retrieved between the three groups (p = 0.04). Pair-wise analysis 
showed a significantly higher number of oocytes retrieved with the GnRH agonist long 
compared to the GnRH agonist short regimen (4.42 ± 3.06 vs. 2.71 ± 1.60, p = 0.01), whilst 
there was no significant difference between the GnRH agonist long compared to the GnRH 
antagonist regimen (4.42 ± 3.06 vs. 3.30 ± 2.91, p = 0.21).There was no significant difference 
in the mean number of mature oocytes retrieved in cycles that had IVF with ICSI in each of 
the three regimens. Seventeen cycles in the GnRH agonist long regimen, 12 cycles in the 
GnRH agonist short regimen and 10 cycles in the GnRH antagonist regimen had ICSI. There 
was no significant difference in the overall fertilisation rate between the three regimens (p = 
0.28). 
 
Significantly higher number of cycles reached embryo transfer with the GnRH agonist long 
regimen compared to the GnRH agonist short and the GnRH antagonist regimens (24 vs. 17 
vs. 13, p = 0.02). There was no significant difference in the mean number of embryos 
transferred and the number of cycles that had embryos frozen in the three regimens (p = 050 
and 0.95 respectively).  
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 Table 6.3 shows the pregnancy results for the women randomised into the study. The overall 
pregnancy, clinical pregnancy and ongoing pregnancy rates for the entire sample were 16.2%, 
13.5% and 10.8%. The ongoing pregnancy rate was 8.1% in group A versus 8.1% in Group B 
versus 16.2% in group C (p=0.48). The study was not powered to detect significant 


















Group C  
(n= 37) 
Age in years (Mean ± SD) 36.7 ± 2.6 36.9 ± 2.8 37.4 ± 3.4 
BMI (Mean ± SD) 24.4 ± 3.8 23.7 ± 4.2 24.2 ± 3.9 
Duration of infertility in 
years (Mean ± SD) 3.6 ± 2.3 4.2 ± 2.7 4.3 ± 3.2 












Number of previous IVF 
attempts (Mean ± SD) 1.5 ± 1.1 1.2 ± 0.5 1.5 ± 1.2 
Previous IVF attempts with 
poor response (Mean ± SD) 1.1± 0.5 1.1± 0.2 1.1± 0.2 
Previous pregnancies  















Previous IVF pregnancies: 



























Serum FSH (IU/l) 
(Mean ± SD) 10.5 ± 5.5 10.4 ± 4.6 10.8 ± 3.4 
Serum oestradiol (pmol/l) 
(Mean ± SD) 170.6 ± 155.8 210.10 ± 201.6 198.0 ± 183.5 
Antral Follicle Count  

















p value  
A versus B 
p.value 
A versus C 
p.value 
B versus C 
p.value 
Duration of 
stimulation in days 
(Mean ± SD) 
12.4 ± 2.7 10.5 ± 2.4 10.5 ± 2.5 0.006 0.005 0.009 0.91 
Total (IU) 
gonadotrophin 








retrieval N (%) 
3 (8.1%) 4 (10.8%) 6 (16.2%) 0.82 
 
Number of oocytes 
retrieved  
(Median, IQR) 












3.30 ± 2.91 
0.04 0.01 0.21 0.34 
Mature oocytes (in 
ICSI) 
(Median, IQR) 
(Mean ± SD) 
 
3, 2 
3.59 ± 2.83 
 
1.5, 3 
1.92 ± 1.67 
 
3, 3 
3.30 ± 1.83 
0.15 0.06 0.75 0.08 
Fertilisation rate 
(%)  52.4% 48.6% 49.4% 0.28 0.52 0.18 0.61 
Cycles reaching 
embryo transfer N 
(%) 





1.7 ± 0.5 1.6 ± 0.5 1.8 ± 0.6 0.50 0.91 0.31 0.32 
 
Cycles with frozen 
embryos N (%) 







 Table 6.3: Pregnancy results of women randomised into PRINT 
Pregnancy results GnRH agonist 
long regimen: 
Group A (n= 37) 
GnRH agonist 
short regimen: 
Group B (n= 37) 
GnRH antagonist 














N (%)  
6 (16.2 %) 
 
3 (8.1 %) 
 





3 (8.1 %) 
 
3 (8.1 %) 
 





This study which was powered to detect a difference in the number of oocytes retrieved 
between the three regimens demonstrates that the GnRH agonist long regimen is effective for 
women with a previous poor ovarian response. Significantly higher numbers of oocytes were 
retrieved with the GnRH agonist long regimen compared to the GnRH agonist short regimen 
and more cycles reached embryo transfer with the GnRH agonist long regimen compared to 
the GnRH agonist short and GnRH antagonist regimens. The study demonstrates the use of a 
higher total gonadotrophin dose and longer duration of stimulation with the GnRH agonist 
long regimen compared to the agonist short and antagonist regimens as has been reported 
previously (Pandian et al., 2010).  
 
The results of this study which demonstrated a higher number of oocytes with the GnRH 
agonist long regimen compared to the GnRH agonist short regimen accords with other 
studies. A recent retrospective study comparing the GnRH agonist long versus the GnRH 
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 agonist short versus the GnRH agonist short minidose versus the GnRH antagonist regimens 
in poor responders showed the number of oocytes and mature oocytes to be significantly 
higher with the GnRH agonist long regimen compared to the GnRH agonist short minidose 
regimen (Madani et al., 2012). A meta-analysis comparing the comparing the agonist short 
and long protocols in women undergoing IVF showed a higher number of oocytes retrieved 
and pregnancy rates with the long protocol (Daya 2000). The inferior outcome with the 
agonist short protocol could perhaps be explained by the elevated progesterone levels during 
the early follicular phase as a result of the initial flare effect of the GnRH agonist which has 
shown to impair follicular recruitment (Sims et al., 1994). 
 
This is the first RCT comparing these three commonly used regimens in women with 
previous poor ovarian response. The strength of this study lies in the criteria used to define 
poor ovarian response; including women with cycles cancelled as a result of ≤ 3 mature 
follicles or ≤ 3 eggs retrieved following maximal stimulation with at least 300 IU of 
gonadotrophin per day as it has been shown that low oocyte numbers (< 4) or cycle 
cancellation is only detrimental to the outcome following a gonadotrophin dose of ≥ 300 IU/ 
day (Kailasam et al., 2004). The major draw back with previous studies on poor responders is 
the lack of a stringent, evidence based inclusion criteria leading to clinical heterogeneity 
within studies as highlighted in Chapter 2. Previous studies defined poor responders based on 
age, baseline serum FSH level, and peak serum oestradiol level. Age and basal FSH levels are 
not sensitive predictors of poor ovarian response (Broekmans et al., 2006) and the number of 
oocytes retrieved has been shown to be a better prognostic parameter than the peak oestradiol 
levels in predicting IVF treatment outcome (Dor et al., 1992). The methodological rigour of 
this study as detailed in Chapter 3 (such as measures taken to ensure allocation concealment, 
blinding of assessors) minimized any potential biases thereby making the results credible. 
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 One of the criticisms could be that the study was not powered to detect differences in 
pregnancy rates. However, to power such a study in poor responders would require a very 
large sample size because of the low pregnancy rates in these women; so large (nearly 200 
women in each arm) as to make the study impractical. Illustration of the strong relationship 
and the initial linear association between egg number and live birth following IVF treatment 
(detailed in Chapter 4) justifies using egg number as an outcome variable in studies of poor 
ovarian response. 
 
In conclusion this study has shown that the standard agonist long regimen is efficacious for 
the management of poor responders and the agonist long and the antagonist regimens offer a 
suitable choice for ovarian stimulation in poor responders. The GnRH agonist short regimen 
is less effective and its use for poor responders should be questioned. 
 
Information from this study is likely to prove useful in the management and counselling of 
poor responders. Women with previous poor ovarian response can be informed of their 
expected pregnancy rates when faced with the decision of undergoing a subsequent IVF cycle 
or considering the option of egg donation. 
 
The question of whether adjunctive agents can modulate or improve the outcome of poor 









Androgen supplementation for poor ovarian 
response in IVF treatment 
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 7.1 Background 
In recent years a number of studies have suggested that androgen supplementation may 
improve outcome in poor responders undergoing COH (Casson et al., 2000; Goswami et al., 
2004, Garcia-Velasco et al., 2005; Barad and Gleicher 2006; Massin et al., 2006; Barad et al., 
2007; Schoolcraft et al., 2008; Fabregues et al., 2009; Ozmen et al., 2009; Yarali et al., 2009; 
Wiser et al., 2010; Kim et al., 2011). Androgens proposed as adjuvants for COH are 
testosterone, dehydroepiandrosterone (DHEA) and the androgen modulating agent, letrozole. 
In a recent world wide survey, over a quarter of IVF clinicians (25.8%) surveyed in 45 
countries stated that they add DHEA as an adjuvant to IVF protocols in women with poor 
ovarian response (IVF Worldwide Survey, 2010). DHEA is a crucial precursor steroid to 
human sex steroid synthesis and is converted to androgens or oestrogens based on the 
expression of steroidogenic enzymes present in peripheral target tissues, including the 
ovarian follicle (Haning et al., 1993). DHEA, of predominantly adrenal but also ovarian 
origin, is the major source of androgen synthesis in women, following its conversion via 
androstenedione to testosterone (Arlt et al., 1998) and exogenous DHEA can serve as an 
androgen replacement tool in women (Arlt et al., 1999). Letrozole is a highly selective, non-
steroidal aromatase inhibitor which blocks the conversion of androgen substrate to oestrogen 
in the granulosa cells, thereby causing raised intra-ovarian androgens. 
 
In this chapter, I will explore the mechanism of action of androgens in folliculogenesis, 
examine the evidence and consider the use of androgens in women with either proven or 
expected poor ovarian response. 
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 7.2 Androgens in folliculogenesis  
In mice oestrogens promote ovarian follicular growth and granulosa cell proliferation (Payne 
and Runser 1959; Smith and Bradbury 1961), but in primates they are either inactive or exert 
an inhibitory effect on ovarian folliculogenesis (Dierschke et al., 1994; Zelinski-Wooten and 
Stouffer 1996; Koering et al., 1994). According to the two cell / two gonadotrophin theory, 
androgens play an essential role in ensuring adequate follicular steroidogenesis in humans 
(Ryan et al., 1968). Produced primarily by the theca cells they are believed to act as a 
substrate for the aromatase activity of the granulosa cells, which converts them to oestrogens. 
Androgens exert a direct autocrine and/ or paracrine effect to regulate follicular function and 
immunohistochemistry studies have identified androgen receptor expression in human 
follicles (Horie et al., 1992; Suzuki et al., 1994). 
 
Androgen receptors are abundant in the granulosa cells of healthy preantral and antral 
follicles of rhesus monkeys and their expression is up-regulated by androgen administration 
(Weil et al., 1998; Vendola et al., 1998). Androgens also augment FSH receptor expression in 
the granulosa cells and have been thought to promote follicular growth and oestrogen 
biosynthesis by amplifying the effects of FSH in rhesus monkeys (Weil et al., 1999). In a 
study on murine models of conditional granulosa cell and oocyte-specific deletion of the 
androgen receptor, a positive correlation between androgen receptor and FSH receptor 
expression was found, supporting the notion that androgens may prevent pre antral follicle 
growth and prevent atresia (Sen and Hammes 2010). Similarly, it has been recently shown 
that in human granulosa cells from small antral follicles, androgen receptor mRNA and 




 Taken together, there thus appears to be a body of evidence which suggests that androgens 
may have a specific action in pre antral and small antral follicles, prior to serving as a 
substrate for oestradiol synthesis in larger follicles.  
 
7.3 Androgen supplementation for poor responders: a systematic review 
and meta-analysis  
Given the underlying biological rationale, along with data from studies on exogenous DHEA 
replacement in women (Morales et al., 1994; Diamond et al., 1996; Casson et al., 1998), 
Casson and colleagues first postulated the hypothesis that oral administration of DHEA 
before gonadotrophin stimulation would improve ovarian response in poor responders. There 
have been several studies since, on androgen supplementation in poor responders undergoing 
IVF treatment. I therefore conducted a systemic review of the literature and a meta-analysis 
to summarise the existing evidence on the role of adjuvant androgens and androgen 
modulating agents in the management of poor responders undergoing IVF treatment. 
 
7.4 Materials and methods 
The following electronic databases, MEDLINE (1950 to March 2011), EMBASE (1980 to 
March 2011), Cochrane library, Web of Science and National Research Register were 
searched for relevant studies. A combination of Medical Subject Headings (MeSH) and text 
words were used to generate three subsets of citations; including studies of poor responders 
(‘poor ovarian response’, ‘poor respon*’, ‘low respon*’), studies of IVF (‘fertilization in 
vitro’, ‘IVF’, ‘intracytoplasmic sperm injection’, and ‘reproductive techniques assisted’), and 
studies of androgens (‘testosterone’, or ‘dehydroepiandrostereone’ or ‘DHEA’ or ‘letrozole’ 
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 or ‘aromatase inhibitor). These subsets were combined using ‘AND’ to generate a subset of 
citations relevant to the question. The reference lists of all known primary and review articles 
were examined to identify cited articles not captured by electronic searches. 
 
7.4.1 Study selection and data extraction 
Studies were selected if the target population was poor responders undergoing IVF ± ICSI 
treatment. Studies were included if they were of randomised design, the intervention group 
consisted of women with androgen supplementation (testosterone, DHEA) or androgen 
modulating drug (letrozole) as adjuvant, and the control group consisted of women with no 
adjuvant or placebo. The primary outcome measure was the ongoing pregnancy/ live birth 
rate and the secondary outcome measures were number of oocytes retrieved, clinical 
pregnancy rate and total gonadotrophin dose. 
 
The selected studies were assessed for methodological quality by using the components of 
study design that are related to the internal validity (CRD Report Number 4, 2001). 
Information on the adequacy of randomisation, allocation concealment, blinding, ITT 
analysis and follow up rates was sought by examining the full text articles. Study 
characteristics such as population features and interventions were extracted from each study. 
 
7.4.2 Statistical analysis 
Relative risks from individual studies were meta-analysed using fixed effects (Mantel and 
Haenszel, 1959) and random effects models as appropriate (DerSimonian and Laird, 1986). 
Heterogeneity of the exposure effects was evaluated graphically using forest plots (Lewis and 
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 Clarke, 2001) and statistically using the I2 statistic to quantify heterogeneity across studies 
(Higgins and Thompson, 2002). Exploration of the causes of heterogeneity was planned using 
variation in features of population, exposure and study quality. Sensitivity analyses was 
performed based on the type of the drug used (testosterone and DHEA or letrozole). 




7.5.1 Study selection process 
The study selection process is detailed in Figure 7.1. A total of 236 citations were retrieved 
from the electronic searches and following examination of the reference lists of the primary 
articles. Of the 236 citations identified, 16 studies were selected during the initial screening 
of abstracts. Following examination of manuscripts 10 studies were excluded with the 
following reasons, six studies were prospective self controlled studies (Casson et al., 2000; 
Mitwally and Casper, 2002; Balasch et al., 2006; Barad et al., 2006; Fernandez-Shaw et al., 
2008; Sonmezer et al., 2009); four studies were non-randomised controlled trials, of which 
three studies involved adjuvant letrozole (Garcia-Velasco et al., 2005; Schoolcraft et al., 
2008; Yarali et al., 2009) and one study looked at DHEA supplementation (Barad et al., 
2007).  
 
Six RCTs which included of 362 women were identified that satisfied the selection criteria 
for the review. Two RCTs compared letrozole versus no letrozole (Goswami et al., 2004, 
Ozmen et al., 2009), three RCTs compared testosterone versus no testosterone 
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 supplementation (Massin et al., 2006, Fabregues et al., 2009; Kim et al., 2011) and one RCT 
compared DHEA versus no DHEA supplementation (Wiser et al 2010). 
 
7.5.2 Quality of included studies 
All the six RCTs had undertaken allocation concealment. The method of randomisation was 
not clearly documented in one study (Ozmen at al., 2009), two out of the six studies had 
blinding (Goswami et al., 2004; Massin et al., 2006) and only one study had placebo in the 
control group (Massin et al., 2006). The quality and the main characteristics of the included 
studies are presented in Tables 7.1 and 7.2. 
 
Figure 7.1: Study selection process for systematic review of adjuvant androgens for poor 











Citations excluded after screening 
titles and/ or abstracts: n = 220 
Total number of citations retrieved from electronic searches and from 
examination of reference lists of primary and review articles: n = 236 
Full manuscripts retrieved for detailed evaluation: n = 16 
Articles excluded with reasons: 
• Inappropriate study design: n = 10 
 
Primary articles included in systematic review: n = 6 
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 Table 7.1: Quality of studies included in the review of adjuvant androgens in poor responders 
 











tables with 1:2 
randomization 
between cases and 
controls 
Yes Yes Yes >95% 
Massin, 2006 Allocation 
sequence generated 
by a random 
permutation table 
(blocks of four) 
Yes Yes Yes >95% 






Yes No Yes >95% 
Kim, 2011 Computer 
generated random 
numbers 
Yes No Yes >95% 
Wiser, 2010 Computer 
generated random 
numbers 




 Table 7.2: Characteristics of the studies included in the review of adjuvant androgens in poor responders 
 





COH protocol Outcomes 
Goswami, 
2004 
Women who had 1-3 
failed IVF due to 
poor ovarian response 
(no definition). 
Women with FSH 
>12 were excluded 
Cases – 13 
Controls - 25 
Cases- letrozole 
Control – none 
Cases – letrozole 2.5 
mg orally days3-7 
followed by rFSH 75 
IU/ day days3-8  
Controls – GnRH 
agonist long regimen 
with FSH 300-450 IU/ 
day 
Total gonadotrophin dose 
Cancelled cycles  
Number of oocytes 
retrieved 
Clinical pregnancy rate 
Massin, 2006 Women with poor 
ovarian response in a 
previous cycle. Poor 
ovarian response 
defined as peak 
serum E2 level 
<1200pg/ml on day 
of hCG or <5oocytes 
retrieved in previous 
cycle or decreased 
ovarian reserve 
defined as FSH >12 
IU/l, E2 - >70 pg/ml 
or inhibin B <45 
pg/ml 
Cases – 24 
Controls - 25 
Cases- 
testosterone gel 
Control – placebo 
Cases – 1 gm 
testosterone gel/day 
(10% absorption) for 
15-20 days during the 




COH regimen same for 
both groups 
Total gonadotrophin dose 
Cancelled cycles  
Number of oocytes 
retrieved 
Number of mature 
oocytes  
Clinical pregnancy rate  
Live birth rate 
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 Table 7.2 continued 





COH protocol Outcomes 
Ozmen, 2009 Women with poor 
ovarian response in a 
previous cycle. Poor 
ovarian response 
defined as cycle 
cancellation due to 
E2 <130 pg/ml on 
day 6 or <450 pg/ml 
on day of hCG. or <4 
oocytes retrieved 
Cases – 35 
Controls - 35 
Cases- letrozole 
Control – none 
Cases- 5 mg letrozole 
orally on days3-7 with 
450 IU/day 
gonadotrophin started 
on day 5. 
Control – 450 IU/day 
gonadotrophin started 
on D3. 
Both groups had GnRH 
antagonist regimen 
Total gonadotrophin dose 
Cancelled cycles  
Number of oocytes 
retrieved 
Number of mature 
oocytes  
Clinical pregnancy rate  
Fabregues, 
2009 
Women with poor 
ovarian response 
defined as 
cancellation of first 




300 IU of 
gonadotrophin daily 
Cases – 31 
Controls - 31 
Cases – 
testosterone 
Controls - none 
Cases –trasnsdermal 
testosterone with a 
daily single patch of 
2.5 mg/ day during the 
5 days preceding 
ovarian stimulation 
with the standard 
GnRH agonist long 
regimen 
Controls – high dose 
gonadotrophin with a 
minidose GnRH long 
agonist regimen 
Total gonadotrophin dose 
Cancelled cycles  
Number of oocytes 
retrieved 
Number of mature 
oocytes retrieved 
Clinical pregnancy rate 
Miscarriage rate 
Ongoing pregnancy rate 
148 
 
 Table 7.2 continued 





COH protocol Outcomes 
Kim, 2011 Women with poor 
ovarian response in a 
previous IVF cycle 
defined as retrieval of 
≤ 5 oocytes despite 
high gonadotrophin 
use (total dose > 2500 
IU) 
Cases – 55 









5mg/day for 21 




Controls - none 
Cases – 12.5 mg 
testosterone gel/day 
(1.25 mg/day nominal 
delivery rate) for 21 
days starting from day 
6 of oestrogen and 
progestogen pre 
treatment 
Both groups had GnRH 
antagonist regimen 
Total gonadotrophin dose 
Number of oocytes 
retrieved 
Number of mature 
oocytes retrieved 
Clinical pregnancy rate 
Live birth rate 
Wiser, 2010 Women with poor 
ovarian response in a 
previous IVF cycle 
defined as retrieval of 




300 IU of 
gonadotrophin daily 
Cases – 17 
Controls - 16 
Cases – DHEA 
Controls - none 
Cases – DHEA 75 mg 
orally once a day for 6 
weeks before ovarian 
stimulation 
All women had 
standard GnRH agonist 
long regimen with 450 
IU of rFSH and 150 IU 
of rLH 
Number of oocytes 
retrieved 
Clinical pregnancy rate 
Miscarriage rate 
Live birth rate 
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 7.5.3 Study outcomes 
Primary outcome 
Ongoing pregnancy/ live birth rate 
Meta-analysis of the four RCTs (Massin et al., 2006; Fabregues et al., 2009; Kim et al., 2011; 
Wiser et al., 2010) out of six, that reported the outcome of ongoing pregnancy/ live birth 
showed a significantly higher ongoing pregnancy/ live birth rate in the androgen 
supplementation group compared to those without (RR 2.08; 95%CI 1.10, 3.93; p = 0.02, 
Figure 7.2). Three RCTs out of the four used adjuvant testosterone (Massin et al., 2006; 
Fabregues et al., 2009; Kim et al., 2011) and one RCT used DHEA (Wiser et al., 2010). The 
two RCTs of letrozole in poor responders (Goswami et al., 2004; Ozmen et al., 2009) did not 
report ongoing pregnancy or live birth as an outcome. 
 
Figure 7.2: Meta-analysis of the trials of adjuvant androgens in poor responders for outcome 





 Secondary outcomes 
Clinical pregnancy 
All studies reported clinical pregnancy as an outcome. As systemic androgen administration 
has a different mode of action on the ovary compared to androgen modulating agents a 
separate sub-group analysis was performed for studies using letrozole and those using 
testosterone or DHEA as adjuvants. Meta-analysis of the four RCTs of adjuvant testosterone 
or DHEA (Massin et al., 2006; Fabregues et al., 2009; Wiser et al., 2010; Kim et al., 2011) in 
the study group showed a significantly higher clinical pregnancy rate in the androgen 
supplementation group compared to the control group (RR 2.06; 95% CI 1.17, 3.61; p = 0.01, 
Figure 7.3). Sensitivity analysis of the two RCTs that used letrozole (Goswami et al., 2004; 
Ozmen et al., 2009) showed no significant difference in the clinical pregnancy rate (RR 1.30; 
95% CI 0.60, 2.83; p = 0.51). 
 
Figure 7.3: Meta-analysis of the trials of adjuvant androgens in poor responders for outcome 





 Number of oocytes retrieved 
Pooling of results of the four RCTs of adjuvant testosterone or DHEA (Massin et al., 2006; 
Fabregues et al., 2009; Wiser et al., 2010; Kim et al., 2011) showed no significant difference 
in the number of oocytes retrieved between the androgen supplementation and control groups 
(WMD 0.51; 95% CI -0.66, 1.68; p = 0.39). Meta-analysis of the two RCTs that used 
letrozole (Goswami et al., 2004; Ozmen et al., 2009) also showed no significant difference in 
the number of oocytes retrieved between the letrozole supplementation and control groups 
(WMD -0.25; 95% CI -0.83, 0.33; p = 0.40). 
 
Total gonadotrophin dose 
Meta-analysis of the three RCTs of adjuvant testosterone or DHEA (Massin et al., 2006; 
Fabregues et al., 2009; Kim et al., 2011) that reported total gonadotrophin dose as an 
outcome showed a significantly lower gonadotrophin consumption in the androgen 
supplementation group compared to the control group (WMD - 462.66; 95% CI - 612.90,               
- 312.42; p < 0.00001). One RCT of letrozole (Goswami et al., 2004) used a lower daily dose 
of gonadotrophins in the letrozole group compared to the control group and was not included 
in the analysis. The other RCT of letrozole versus control (Ozmen et al., 2009) showed a 
significantly lower gonadotrophin consumption in the letrozole supplementation group 





 7.6 Discussion 
The results of the review show a significant improvement in the clinical pregnancy, ongoing 
pregnancy/ live birth rates with androgen supplementation (testosterone, DHEA) in women 
with poor ovarian response, but the use of the androgen modulating agent letrozole showed 
no significant difference in clinical pregnancy rate compared to controls. The gonadotrophin 
consumption was significantly lower in the androgen supplementation and the letrozole 
groups compared to the controls groups.  
 
This study gives a quantitative estimate of the effect of various androgen supplements and 
modulators used in women with poor ovarian response undergoing IVF treatment. A 
systematic review by Kyrou et al (2009) which evaluated the effectiveness of various 
interventions and adjuvants in poor responders found only one RCT on the use of testosterone 
and one study on the use of letrozole, and showed no benefit with either of these 
interventions (Kyrou et al., 2009). Another systematic review on the use of letrozole in 
normal responders found no significant difference in the pregnancy rate (Requena et al., 
2008). The validity of this study depends on the methodological rigor of the review and the 
component primary studies. A prospective protocol was used, and a concerted effort made to 
find all the evidence. 
 
Despite this review of adjuvant androgens in poor responders showing a significant increase 
in the clinical pregnancy, and in ongoing pregnancy/ live birth rates, it is important to 
highlight the small sample sizes of individual trials, and even when the trials were combined 
in a meta-analysis, only 127 women treated with androgens (testosterone or DHEA) even 
when the trials were combined in a meta-analysis. The wide confidence intervals around the 
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 relative risks for the outcome measures suggest imprecise results, which could be directly 
attributed to the relatively small sample sizes of the studies in this review. The quality of the 
studies was poor with only one out of the six studies using a placebo in the control group 
(Massin et al., 2006). The studies varied in their inclusion criteria (i.e. definition of poor 
ovarian response), type of androgen supplementation (testosterone gel/ patches, oral DHEA), 
the dose and the duration of androgen supplementation. Given the paucity of evidence 
androgen supplementation should not be advocated routinely to poor responders. 
Nonetheless, the demonstration of a potential benefit presents a powerful case for a 
















 8.1 Critical review of the thesis and clinical implications 
The aim of establishing this project was to try and find answers to frequently encountered 
scenarios in the management of women with poor ovarian response undergoing IVF 
treatment. Clinicians face difficulties in making decisions when there is a paucity of good 
data on which to depend. One of these is in the choice of COH regimen for women with poor 
ovarian response. I therefore performed a systematic review and meta-analysis to identify an 
ideal COH regimen for poor responders. The comprehensive review of the literature 
identified several shortcomings in studies relating to poor responders. The systematic review 
found the existing evidence to be inconsistent and inconclusive. It highlighted the lack of a 
uniform definition of poor ovarian response as studies tended to use loose criteria and proxy 
definitions that are not strictly evidence based. From this I was unable to determine an ideal 
COH regimen, and appreciated the need for a well designed RCT to compare the various 
COH regimens used in poor responders which led to PRINT. 
 
PRINT is the first RCT comparing the efficacy of the three commonly used COH regimens 
(GnRH agonist long, GnRH agonist short and GnRH antagonist regimens) in women with 
previous poor ovarian response undergoing subsequent IVF treatment. The inclusion criteria 
for PRINT was based on a rigid evidence-based definition of poor ovarian response as 
justified in Chapter 3, in order to overcome one of the deficiencies with previous studies of 
poor ovarian response. However, the use of a stringent definition created a difficulty with 
recruitment in that enrolment numbers were fewer and harder to achieve than projected. To 
overcome this difficulty, PRINT was extended to a second site. The Lister Fertility Clinic, 
London was identified as suitable as this centre works to similar high standards but carries 
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 out more IVF cycles than at the ACU, Guy’s and St Thomas’ NHS Foundation Trust, 
London, and therefore was likely to have more eligible women. 
 
Setting up PRINT initially at site one followed by its extension to the second site was by no 
means an easy task. As PRINT was the first CTIMP that was set up at the ACU in accordance 
with the then newly introduced Medicines for Human Use (Clinical Trials) Amended 
Regulations 2006, following the new research governance procedures was a learning process 
for me. Individual exhaustive applications had to be made to the REC, MHRA and the R&D 
department. Awaiting responses from respective regulatory authorities entailed frustrating 
delays. Perhaps a system whereby a single simultaneous application could be made to all the 
regulatory authorities would make the task of initiating such a study less laborious. 
 
Maintaining the enrolment of participants into PRINT was a considerable challenge. An 
infuriating difficulty was that certain clinicians advocating their preferred regimen despite the 
lack of evidence supporting their preference. I tried to overcome this counterproductive view 
to an extent by holding regular updates, meetings and sending e-mail reminders to recruit 
eligible women into PRINT. The fact that I was based at the Guy’s ACU and was very pro-
active in identifying every eligible participant and constantly reminding clinicians, seemed to 
have helped at that site. However, enrolment at the Lister Fertility Clinic was poor despite 
clinicians at the centre apparently endorsing PRINT at the several meetings I had with them. 
Whether a more frequent physical presence at that site, or having a clinical fellow assistant 
there would have made a difference is something that has to be considered. Also, PRINT was 
the first ever RCT to be set up at the Lister Fertility Clinic which is primarily a private 
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 fertility unit in comparison to the ACU which is part of an established Academic Health 
Centre. 
 
A criticism of PRINT might be that the study was not powered to detect differences in 
pregnancy outcome as PRINT was designed and powered to detect differences in the number 
of oocytes between the three regimens. However, as discussed in Chapter 6 such a study 
would be impossible due to the large sample size needed, given that poor responders have 
very low pregnancy rates. The relationship between the number of oocytes retrieved and live 
birth following IVF was therefore explored to establish whether the number of oocytes could 
be used as a surrogate outcome measure in IVF research. It was thought valuable to use 
anonymous data from the HFEA to try and address this question, as it is a vast dataset from 
all centres in the UK, and the results would be more likely to be generalised. Although, it was 
fairly straightforward to obtain the data, interpretation of the large database of over 700,000 
cycles was not easy. The database had to be cleaned and its validity established before any 
analysis could be undertaken. This was a painstaking task with the HFEA having to be 
contacted for clarification on several occasions. My experience in dealing with this database 
raises questions whether the HFEA should be more meticulous in the way their data is 
collected and released for access to researchers given that units across the country and the 
HFEA are investing valuable time and money in collecting the information. 
 
Despite these difficulties and potential shortcomings, work leading to this thesis has 
demonstrated a number of useful outcomes. I have shown that the number of oocytes 
retrieved is an important prognostic variable in predicting IVF success and can be used as an 
outcome measure for research on poor responders. The nomogram devised to predict live 
158 
 
 birth rate for a given oocyte number and female age (discussed in Chapter 4) is useful tool in 
planning stimulation regimens for individual women. Additionally it is useful in counselling 
women especially women with poor ovarian response about their chances of success and 
enables them to make more informed choices regarding future options. 
 
Results from PRINT have shown that the GnRH agonist long regimen is efficacious for poor 
responders. The agonist long and the antagonist regimens offer a suitable choice for ovarian 
stimulation in poor responders and the GnRH agonist short regimen is less effective This 
information is useful for clinicians in their management of poor responders. Publication and 
dissemination of the results of PRINT will help change practices of clinicians in their choice 
of down regulation regimen for poor responders.  
 
It would have been ideal if all women randomised to PRINT had received the allocated 
intervention. Sixteen women randomised to the study changed their initial decision and opted 
not to have further treatment. However, allowance was made for the sample size to 
accommodate drop outs and an ITT analysis was employed, measures which should allay any 
bias to the results. Most women that changed their initial decision did not have further 
treatment due to financial restraints (given that they had to self fund the IVF cycle). This is a 
reflection of what happens in practice in England where most couples are eligible for only 
one NHS funded IVF cycle and would have to self fund any subsequent ones. 
 
Another potential criticism of PRINT could be the use of a gonadotrophin dose of 450 IU/ 
day. At the time of devising the study protocol the decision to go on a dose of 450 IU/ day 
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 was based on existing unit practices and consensus opinion. Although the most extensively 
employed strategy to improve ovarian response in poor responders involves the use of high 
dose gonadotrophins, very few studies have evaluated the effectiveness of such doses 
(Hofmann et al., 1989; Karande et al., 1990; Land et al., 1996; Berkkanoglu and Ozgur, 
2010). An RCT comparing a daily gonadotrophin dose of 300 IU versus 375 IU versus 450 
IU in women with diminished ovarian reserve (AFC < 12) undergoing IVF found no 
significant difference in outcomes between the three groups (Berkkanoglu and Ozgur, 2010). 
However, in a recent worldwide survey on the management of poor responders, the majority 
of IVF cycles had a daily gonadotrophin dose of > 375 IU (IVF-Worldwide, 2010) (Figure 
8.1). Whether a high gonadotrophin dose is likely to enhance outcome in women with poor 
ovarian response still requires further evaluation. 
 












300-375 IU/ day, 
36.7%
150-225 IU/ day, 
11.4%




 A dilemma often encountered in women with poor ovarian response is whether to continue or 
cancel the IVF treatment cycle and start again when few follicles are recruited. Comparison 
of the outcomes of two successive IVF treatment cycles in women with poor ovarian 
response as described in Chapter 5 failed showed any significant intercycle variability thus 
arguing against a cancellation strategy. The limitation of the study was its retrospective 
nature and relatively small numbers. It would be useful to substantiate the findings with a 
prospective study and a larger sample size. 
 
The possible role of androgens in ovarian folliculogenesis and its part in the management of 
poor ovarian response prompted me to investigate the effect of adjuvant androgen 
supplementation in these women undergoing IVF treatment. The systematic review and meta-
analysis on adjuvant androgens for poor responders demonstrated a potential for benefit with 
higher ongoing pregnancy/ live birth rates and lower gonadotrophin consumption in the 
androgen supplementation group. The systematic review however, highlighted the 
shortcomings in the existing evidence and identified the need for a well designed RCT to 
substantiate the evidence. 
 
8.2 Other interventions for poor responders 
In the endeavour for continuous improvement in the outcome of poor responders some other 
treatment regimens/ interventions are being used currently or proposed and merit 
consideration here.  
These include: 
- the use of r-FSH versus urinary derived gonadotrophins 
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 - the addition of recombinant LH (r-LH) to r-FSH during ovarian stimulation 
- use of growth hormone supplementation and other adjuvant therapies 
 
8.2.1 Gonadotrophin type for poor responders 
There is considerable controversy as to whether the type of gonadotrophin used influences 
IVF outcome and this debate also extends to poor responders. The recent worldwide survey 
on the management of poor responders (IVF-Worldwide, 2010) showed a wide variation in 
the choice of gonadotrophin preparations used for poor responders (Figure 8.2).  
 
Figure 8.2: Worldwide survey of gonadotrophin preparations used for poor responders 






 Although results of initial small studies of r-FSH versus urinary derived FSH (u-FSH) in poor 
responders reported a more favourable outcome with r-FSH (Raga et al., 1999; De Placido et 
al., 2000), a larger study found no significant difference for poor responders (Eskander et al., 
2004). Randomised studies evaluating the addition of r- LH to r-FSH in poor responders 
compared with stimulation with r-FSH alone found no significant differences in the number 
of oocytes retrieved, mature oocytes, fertilisation rates and embryo quality (Fernandez 
Ramirez et al., 2006; Barrenetxea et al., 2008). Currently there is inadequate evidence to 
suggest that the IVF outcome of poor responders is influenced by the choice of 
gonadotrophin preparation. 
 
8.2.2 Growth hormone supplementation for poor responders 
Growth hormone is a peptide hormone produced by the anterior pituitary, which is thought to 
play a role in ovarian physiology. Growth hormone has been noted to stimulate ovarian 
follicle growth and steroidogenesis, presumably by amplifying the action of FSH via insulin 
like growth factor–1 (IGF-1) (Davoren and Hsueh 1986). Supplementation of growth 
hormone along with gonadotrophins has been studied to improve the outcome in poor 
responders. Although optimistic results were reported initially (Ibrahim et al., 1991) this has 
not been confirmed in subsequent studies (Shaker et al., 1994; Hughes et al., 1994; Suikkari 
et al., 1996). A systematic review and meta-analysis assessing the effectiveness of growth 
hormone as an adjuvant therapy in poor responders showed that growth hormone addition 
significantly improved IVF treatment outcome (Kolibianakis et al., 2009). However, the 
review highlighted the small sample sizes of the individual studies and called for an 
adequately powered RCT. Growth hormone releasing factor and pyridostigmine, which 
stimulate the release of growth hormone, were also suggested as adjuvants for poor 
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 responders undergoing IVF treatment. However, RCTs of growth hormone releasing factor 
and pyridostigmine in poor responders have failed to show any significant improvement in 
pregnancy rates (Howles et al., 1999; Kim et al., 1999).  
 
8.2 Future research 
My work leading to this thesis has provided answers to important clinical situations that can 
be translated to patient management. However, it has also raised questions about some of the 
current practices for poor responders that need to be examined. Any potential benefit from 
adjuvant androgens and growth hormones in the context of poor ovarian response needs to be 
evaluated by well designed RCTs. The optimal gonadotrophin dose for poor responders also 
needs to be addressed by an RCT. Previous difficulties in studies of poor responders where 
various definitions were used, is now likely to be overcome with the introduction of the 
European Society of Human Reproduction and Embryology (ESHRE) consensus definition of 
poor ovarian response (Ferraretti et al., 2011) which emerged after initiation of PRINT. 
According to the ESHRE consensus, in order to define a poor responder in IVF, at least two 
of the following features must be present: (1) advanced maternal age or any other risk factor 
for poor ovarian response; (2) a previous poor ovarian response; and (3) an abnormal ovarian 
reserve test or two episodes of poor ovarian response after maximal stimulation in the 
absence of advanced maternal age or abnormal ovarian reserve test. It is important that future 





 As the burden of poor ovarian response is largely a consequence of women delaying 
childbearing, interventions to encourage women not to delay may ease the problem by 
primary prevention (Bewley et al., 2005). Advances in the technique of oocyte freezing and 
earlier access, might be more favourably viewed for women who wish to delay childbearing 
for social reasons. Nevertheless, there is ongoing debate whether social egg freezing should 
be promoted in society. Finally, with progress in stem cell research, the production of 
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